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Metabolomic signatures associated with complex disease have been identified. 
Metabolomic profiling and the integration of genomic data have proven to be powerful tools 
to investigate genetic effects underlying intermediate phenotype levels and may facilitate 
improved understanding of pathophysiologic processes of disease. However, most published 
studies did not consider sex as an effect modifier, analyze sex-specific effects, nor gene by 
sex interactions. One reason can be incomplete knowledge of the power of statistical methods 
used in a given dataset. 
I first investigated sex-specific genetic effects by performing sex-stratified exome-
wide association studies for 271 chromatography-mass spectrometry measured metabolites in 
the Atherosclerosis Risk in Communities (ARIC) study, followed by a conventional Z test to 
evaluate the heterogeneity of genetic effects between men and women. We used African-
Americans as the discovery sample and pursued exome-wide significant (false discovery rate 
Q≤ 5%) genes for replication in European-Americans. Overall, we identified and replicated 
variants in 12 genes associated with metabolite levels, one of which, rs11555566 in ADA, 
  
was a novel common variant suggesting a larger effect in men compared to women for 
association with N1-methyladenosine levels. 
I then focused on rare genetic variants and sex interactions on serum metabolite levels 
and evaluated the joint effect of genetic main effects and gene-sex interactions in the same 
discovery and replication population. Using gene-based rareGE and MiSTi approaches, we 
observed and replicated 14 gene-metabolite associations through joint test, three of which 
were novel, including PLA2G7- arachidonate (20:4n6), PTER- N-acetyl-beta-alanine and 
NPC2- leucylserine. Significance of the NPC2- leucylserine association arose from both 
genetic main effects and gene-sex interaction effects.  
Finally yet importantly, I carried out a simulation study to investigate the 
performance of two aforementioned emerging methods in detecting rare variant gene-sex 
interaction effects on a quantitative phenotype. Compared with conventional burden tests, 
rareGE and MiSTi have more power under a wide range of scenarios. Simulation results also 
illustrate that an approach that jointly tests the genetic main effects and gene-sex interactions 
increases statistical power and has the potential to uncover novel genetic signals that have not 
been identified previously.  
In conclusion, our study suggests sex-specific genetic effects on the metabolome, and 
reports novel genetic variants associated with metabolite levels. Use of simulated data 
provides insights into the power and desired sample size in conducting rare variant G×E 
interaction studies for these newly introduced methods, justify their use in practice. 
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CHAPTER I. BACKGROUND 
Literature Review 
Sex Difference in Cardiovascular Disease  
 Cardiovascular disease (CVD) remains the leading cause of mortality across race 
groups for both women and men in the United States (1), but there are substantial sex 
differences in the prevalence and presentation of different CVD (Figure I-1). The percentage 
of adult men living with major manifestations of CVD exceeds those of adult women, except 
for stroke. Men develop coronary artery disease (CAD) earlier and usually present with more 
severe atherosclerosis in their coronary arteries than women, but the risk of heart failure and 
mortality rate following myocardial infarction is higher in women than men (2, 3). Despite 
unfavorable progression of CVD, women may be less likely to receive optimal diagnosis and 
timely treatment because the presentation of symptoms in women with acute coronary 
disease is “atypical”- women are significantly less likely to report chest pain or discomfort 
compared with men (4). Although sex differences in prevalence, age of onset, progression 
and outcome of CVD have been well-documented (5), the biological underpinnings of these 
differences are not well-understood. 
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Figure I-1 Sex difference in cardiovascular disease (CVD) at a glance 
Note: Data adapted from Heart disease and stroke statistics 2017 update: a report from the 
American Heart Association (5) 
 
Sex differences in the epidemiology of CVD may arise from different exposures of 
environmental and lifestyle risk factors, for instance, heavy alcohol consumption, tobacco 
use, and physical inactivity (6, 7). In addition to differences in health-related lifestyles, to 
understand the biological determinants of observed sex differences in CVD, a natural starting 
point is the biological effects of the sex chromosomes (8), and related sex hormones effects, 
such as estrogen levels (9). However, it is also important to consider genetic variants on the 
autosomes that may affect risks of developing CVD differently in women and men. Previous 
studies have identified different genetic variants influencing CVD risk in men compared to 
women, or found significant genotype-sex interactions for CVD or related traits (10-13). For 
example, Silander et al. reported that variants in CPB2 and USF1 genes have a female-
  
3 
 
specific risk for coronary heart disease (CHD) and/or CVD, while a variant (rs2069840) in 
IL6 shows strong association with CVD in men but not in women (12). In a large study of 
more than 200,000 individuals, 49 loci were found to be associated with waist-to-hip ratio, an 
independent risk factor to CVD; 20 of the 49 loci show significant sexual dimorphism, 19 of 
which present a stronger effect in women (13). 
Despite previously reported sexually dimorphic genetic-disease associations (14), 
most large published meta-analyses (15-19) do not take sex differences into account beyond 
adjusting for sex as a covariate (15, 19, 20). Thus, potential sex differences are important 
components for further genetic epidemiologic research of CVD and its risk factors. 
 
Gene-Environment Interactions 
Traditional genome-wide association studies (GWAS) utilizing common genetic 
variants have successfully identified a large number of loci associated with complex diseases 
and traits. However, a large proportion of the heritability of these diseases/traits remains 
unexplained (21). To find the “missing heritability”, rare variants, structural variations, as 
well as gene-environment (G×E) interactions have been suggested to extend beyond straight-
forward genome-wide association approaches (22).  
Gene-environment interactions are defined in this proposal as different effects of a 
genotype on disease risk between differing environmental exposures, including sex. 
Equivalently, GxE interactions may be defined by different effects of an environmental 
exposure on disease risk in persons with different genotypes (23, 24). Studying G×E 
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interactions is important, as it may extend our knowledge of the genetic architecture of 
complex traits and improve our understanding of the underlying mechanisms of common 
diseases for novel and known loci (25-27). Although premature at this point, knowledge of 
gene-sex interactions could lead to different genetic risk algorithms and treatment 
recommendation in men compared to women. 
Since 2010, several large-scale genome-wide G×E studies have successfully 
identified novel loci accounting for the modifying effects of environmental exposures such as 
age, sex, BMI, alcohol consumption, smoking status on CVD-related intermediate traits (28-
37). Although none of the studies directly model clinical defined CVD, using risk factors 
such as blood pressure, lipid profiles, and obesity, these studies have successfully identified 
novel common variant loci related to CVD risk that were not detected via analysis of main 
effects alone. For example, a genome-wide meta-analysis of 114 studies in up to 320,485 
European-ancestry individuals reported 4 novel loci for BMI that showed age-specific 
effects, and 17 novel loci with sex specific effects on BMI (29). Though it is tempting to 
consider conducting an association test within each stratum of environmental exposures, a 
recent study (38) compared a stratified analysis approach and a 2 degree of freedom (DF) 
joint test for studying G×E interactions and suggested that inclusion of G×E interactions is 
important in terms of identifying novel signals, particularly for rare and low-frequency 
variants.  
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Rare Variant G×E Interactions 
Availability of high throughput DNA sequencing technologies and large-scale 
imputation reference panels (39) offer an opportunity to investigate rare and low-frequency 
genetic variants with minor allele frequency (MAF) ≤5% across the genome. Analysis of 
G×E interactions involving rare variants may identify novel loci, and characterize rare 
variant G×E interactions in previous loci identified by GWAS of common variants. However, 
unlike well-established G×E interaction tests for common variants (40, 41), methods 
development for detecting rare variant G×E interactions is challenging for several reasons. 
First, considering typical sample sizes of most published GWAS studies, a single marker test 
is underpowered for rare and low frequency variants. Second, conventional burden tests that 
simply summarize the total number of variants within a region and fit a model for the rare 
variant burden by environment interaction term, often result in inflated type 1 error rates and 
biased estimates when the rare variants and environment are not independent (i.e. G×E 
correlation) (42). 
Recently developed novel approaches for testing rare variant G×E interaction effects 
(42-47) face limitations. Jiao and colleagues (45, 46) treated genetic main effects as fixed 
effects, which may suffer from inflated type I error. Lin et al proposed an interaction 
Sequence Kernel Association Test (42) that is powerful when both positive and negative 
directions of G×E effects exist, yet loses power when the variants in the set have the same 
direction of G×E. Finally, Tzeng (43) assumed comparable magnitude of the variance 
component parameters for genetic main effects and G×E interactions, which may not be true.  
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Further work is underway to overcome the aforementioned limitations. Su et al. 
proposed a novel and rigorous framework to derive independent score statistics for fixed 
effects and the variance component that is more powerful to test G×E interaction terms of 
rare variants (48). A joint test that allows one to simultaneously test genetic main effects and 
interaction effects and requires no assumption about the magnitude of the variance 
component parameters for the genetic main effects and G×E interactions was proposed and 
successfully implemented by Chen and colleagues (49). The former interaction-only test 
allows detecting G×E interactions regardless of the genetic main effect, while the latter joint 
testing approach aims to detect associated genetic effects allowing for G×E interactions. 
Applying these newly developed methods to study rare variant G×E interaction in CVD-
related traits, for instance the metabolomic data that will be reviewed in the next section, may 
improve our understanding of the underlying pathophysiology of disease.  
 
Metabolomics and the metabolome by sex 
Metabolomics is one of the “-omics” disciplines that systematically studies small-
molecule metabolites found in biological samples, such as cells, biofluids, tissues or 
organisms. These metabolites are produced and modified by a variety of chemical and 
physiologic processes, such as amino acid and lipid biosynthesis, carbohydrate anabolism, 
and xenobiotic metabolism. The entire ensemble of small-molecule metabolites presented in 
a biological sample is generally referred as the metabolome. These small-molecule 
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metabolites may reveal pathologic or etiologic pathways to complex diseases because they 
represent intermediates that profile biological status closely related to phenotypes (50). 
At present, there are two major instrument platforms for measuring metabolite levels 
in biological samples, namely nuclear magnetic resonance (NMR) and chromatography 
combined with mass spectrometry (MS)-based metabolic profiling (51-53). There are also 
two major distinct technologic approaches, “untargeted” and “targeted”, to metabolite 
measurements (54). Untargeted metabolomics aims to analyze all of the measureable analytes 
in a sample including unknown chemicals, and targeted metabolomics means to measure an a 
priori defined group of chemically characterized metabolites (e.g. lipids). Several review 
papers have described and contrasted these platforms and approaches (55, 56). 
Acknowledging concerns about the semi-quantitative nature of the untargeted MS-based 
approach, it has notable advantages for detecting and quantifying (at least relative 
quantification) as many metabolites as possible in a biological sample with high sensitivity. 
Therefore applying such an approach is able to achieve high-throughput profiling of the 
metabolome. 
In the past few years, numerous epidemiological studies utilizing metabolomics have 
successfully linked metabolite levels to the etiology and progression of complex diseases 
such as hypertension, CVD and diabetes in individuals with and without European-ancestry 
(57-69). The identified CVD metabolomic signatures include dietary phosphatidylcholine 
metabolites, acylcarnitines (61, 65), as well as several other lipid classes such as 
polyunsaturated fatty acids (FAs) (66, 68, 69). Such metabolomic signatures were involved 
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in CVD risk via various potential mechanisms. For example ω-3 FAs may prevent 
arrhythmias, lower heart rate and blood pressure, decrease platelet aggregation, and lower 
triglyceride levels (70). The latter is accomplished by reducing hepatic very-low-density 
lipoprotein and triglycerides synthesis and secretion and enhancing the triglycerides 
clearance from chylomicrons (71, 72). 
In addition, both traditional GWAS and sequence analyses across the whole genome 
or exome have successfully identified and verified hundreds of genetic loci associated with 
metabolite levels (73-85), and many of them can be further linked to clinically relevant 
factors of disease development. An example of integrating genomics and metabolomics to 
promote novel biomarker discovery and better understand etiologic pathways of complex 
disease is the story of hexadecandioate. In a whole exome sequencing study of African-
Americans, Yu et al. identified a loss-of-function (LoF) variant in SLCO1B1 that was 
associated with increased levels of hexadecanedioate, which for the first time, was reported 
for its relationship with heart failure risk (81). Hexadecanedioate, a long-chain dicarboxylic 
acid, was also reported to be significantly associated with increased blood pressure and 
mortality (59, 81). The aforementioned genetic and metabolomic evidence together 
implicated a potential pathway for heart failure and opened up the possibility of further 
hypothesis tests and experimental studies.  
Limited work has been done that shows that the metabolomic profiles of men and 
women are different, and sex-specific metabolism-related genetic polymorphisms have been 
identified through sex-stratified GWAS in European-ancestry populations (86, 87). Pathway 
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analysis has revealed gender-specific pathway differences in the serum metabolome (87). 
Moreover, a single-nucleotide polymorphism (SNP) in CPS1 rs715 that previously showed a 
strong sex difference in association with glycine (86), yields a strikingly significant and 
protective association with decreased risk of CAD only in women (88). Metabolomics 
studies also reveal the sex-specific effects of a SNP rs646776 in SORT1, a known low-
density lipoprotein cholesterol locus (89). Additional systematic studies are needed to better 
understand the modifying effect of sex on the human metabolome and its genetic 
determinants with a particular focus on rare variants. Additionally, current understandings of 
sex differences in the metabolome have solely originated from studies in European-Ancestry 
populations and there is a need for expanding these studies to underrepresented populations, 
such as African-Americans (AAs). 
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Public Health Significance 
There are encouragements from the National Heart, Lung, and Blood Institute 
(NHLBI) for conducting additional research addressing the public health concerns of sex 
differences in cardiovascular diseases (90). Although significant sex-related differences in 
CVD epidemiology are appreciated (1, 5), less effort has been devoted to uncovering its 
etiology. Studies that go beyond common single nucleotide variants to investigate the role of 
rare genetic variants as well as studies with more complex statistical analyses to evaluate the 
impact of sex alteration of disease phenotypes are warranted.  
It is generally accepted that complex diseases such as CVD are not only caused by 
genetic or environmental factors alone, but also the interactions between them (26). Serum 
metabolite levels ultimately are the reflections of functional activities of genes and 
environmental exposures (91, 92). Given the nature of metabolite levels and numerous 
aforementioned work that have linked metabolites to complex diseases, they can serve as 
ideal intermediates to understand the effects of G×E interactions on complex diseases. Rare 
and low frequency (MAF≤5%) variants make up the vast majority of the genetic variation in 
the genome (93), and may account for part of the missing heritability along with G×E 
interactions (22). Studying the integration of rare and low frequency genetic variants, sexual 
dimorphism, and metabolomics may improve our comprehensive understanding of the 
underlying pathophysiology. To date, there is no study systematically utilizing and 
comparing methods developed for testing rare variant G×E interactions in large-scale human 
population data. In addition, investigating gene-sex interactions or sex-specific genetic 
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variants related to CVD-related traits has not been done in AAs. New studies focusing on 
AAs will help address this important knowledge gap.  
This dissertation research leverages existing data from a large population-based 
multi-ancestry cohort: the Atherosclerosis Risk in Communities (ARIC) study that contains 
well-characterized AA and European-American (EA) participants to investigate whether 
there are sex-specific differences in the genetic determination of serum metabolome levels. 
As mentioned above, the serum metabolome may serve as an ideal surrogate/biomarker for 
disease status, including CVD. Therefore, Chapter 2 of this dissertation describing the sex-
specific genetic effects on the serum metabolome responds to the aforementioned rising 
public health concerns on sex-related differences in CVD-related phenotypes (20, 22, 90). 
Chapters 3 and 4 address the challenge of testing rare variant G×E interactions through 
estimating gene-sex interactions on the serum metabolome with a particular focus on rare and 
low-frequency genetic variants using two emerging methods, and comparing the power of 
differing methods in simulation studies. Chapter 5 presents a summary of the findings and a 
perspective about further rare and low-frequency genetic variant G×E interaction studies. 
The results of this dissertation are expected to offer new evidence about sex-specific 
genetic influences on the human metabolome and report novel genetic variants that were not 
previously identified when gene-sex interaction parameters were omitted in previous studies. 
This dissertation will also provide insights into the power and desired sample size for 
conducting rare variant G×E interaction studies, which may advance the understanding of 
current G×E interaction results and benefit future studies. 
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CHAPTER II. SEX-SPECIFIC GENETIC EFFECTS ON THE SERUM 
METABOLOME IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) 
STUDY 
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Abstract  
Metabolomic signatures associated with complex disease, such as cardiovascular 
disease, have been identified. Metabolomic profiling and the integration of genomic data 
have proven to be powerful tools to investigate genetic effects underlying intermediate 
phenotype levels and may facilitate improved understanding of pathophysiologic processes 
of disease. However, most published studies did not consider sex as an effect modifier, 
analyze sex-specific effects, nor gene by sex interactions. This study investigated sex-
specific genetic effects on serum metabolite levels and evaluated the estimated heterogeneity 
of genetic effects between men and women. We analyzed 3,540 individuals from the 
Atherosclerosis Risk in Communities (ARIC) study with metabolite measurements and 
exome chip genotyped data. We performed sex-stratified exome-wide association studies for 
271 chromatography-mass spectrometry measured metabolites in ARIC African-Americans 
as the discovery sample and pursued exome-wide significant (false discovery rate Q<5%) 
genes for replication in European-Americans. We identified and replicated variants in 12 
genes through either common single variant analysis or gene-based burden tests in sex-
stratified exome-wide association analyses. For example, rs11555566 in ADA is a novel 
common variant associated with N1-methyladenosine levels. Results of rs11555566 
suggested a larger effect in men (estimated effect size 0.18-0.22) as compared to women 
(estimated effect size 0.14-0.17), but the difference was not significant. Variants in 6 genes 
suggested differing genetic effects on metabolite levels observed through testing for 
difference of the effect size estimates in sex-stratified results, although the difference 
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between sexes was not replicated. Our study suggests that sex-specific genetic effects of 
metabolites may exist, but the lack of consistency in testing sex differences of the genetic 
effects between discovery and replication samples underscores that future studies should 
consider sex-specific effects with enhanced statistical methods and tools. 
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Introduction 
Metabolomics is one of the “-omics” disciplines that systematically studies small-
molecule metabolites found in biologic samples such as cells, biofluids, tissues or organisms. 
These metabolites are produced and modified by a variety of chemical and physiologic 
processes, such as amino acid and lipid biosynthesis, carbohydrate anabolism, and xenobiotic 
metabolism. The ensemble of small-molecule metabolites presented in a biologic sample is 
referred to as the metabolome. These small-molecule metabolites may reveal pathologic or 
etiologic pathways to complex diseases because they represent intermediates that at least 
partially profile the biological status of an individual and are closely related to a number of 
risk factor and disease-related phenotypes (1).  
Numerous epidemiologic studies utilizing metabolomics have successfully related 
metabolite levels to the etiology and progression of complex diseases such as hypertension, 
cardiovascular disease CVD, and diabetes in both Whites and non-Whites (2-14). In addition, 
both traditional genome-wide association studies (GWAS) and sequencing analyses across 
the whole genome or exome have successfully identified and verified hundreds of genetic 
loci with metabolite levels (15-25), and many of them can be further linked to clinically 
relevant factors of disease development. An example of integrating genomics and 
metabolomics to promote novel biomarker discovery and better understand the etiological 
pathways of complex disease is the story of hexadecandioate. In a whole exome sequencing 
study of African-American population, Yu et al. identified a loss-of-function (LoF) variant in 
SLCO1B1 that was associated with increased levels of hexadecanedioate, which for the first 
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time, was reported to be associated with incident heart failure (23). Hexadecanedioate, a 
long-chain dicarboxylic acid, was also reported to be significantly associated with increased 
blood pressure and mortality (4, 23). The aforementioned genetics and metabolomics 
evidence together implicated a potential novel pathway for heart failure and opens up the 
possibility of further hypothesis testing and experimental studies. 
Limited work has shown that the metabolomic profiles of men and women are 
different, and sex-specific metabolism-related genetic polymorphisms have been identified 
through sex-stratified GWAS (26, 27). Pathway analysis has also revealed sex-specific 
pathway differences in the serum metabolome (27). Moreover, a single-nucleotide 
polymorphism (SNP), rs715 in CPS1, that previously showed a strong sex difference in 
association with glycine (26), yields a strikingly significant and protective association with 
decreased risk of coronary artery disease only in women (28). Metabolomics studies also 
reveal the sex-specific effects of a SNP rs646776 in SORT1, a known low-density lipoprotein 
cholesterol locus (29). Additional and systematic studies are needed to better understand the 
modifying effect of sex on the human metabolome and its genetic determinants. Additionally, 
current understanding of sex differences in the metabolome has solely originated from 
studies in Whites, and there is a need for expanding these studies to underrepresented 
populations, such as African-Americans (AAs). Therefore, we investigated whether there are 
sex-specific differences in the genetic effects on the metabolome using a subset of AAs in the 
Atherosclerosis Risk in Communities (ARIC) study, and examined the replication of these 
sex-specific effects in European-Americans (EAs) from the ARIC study. 
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Methods 
Study Sample 
The ARIC study is a population-based prospective cohort study of 15,792 adults from 
four U.S. communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; 
and Washington County, MD), which has been described in detail previously (30). ARIC 
included both EAs and AAs aged 45-64 at the baseline examination (1987-1989). 
Participants completed three additional triennial follow-up examinations, a fifth exam in 
2011-2013, and a sixth exam in 2016-2017. Included in this analysis were 3,540 participants 
with metabolite measurements and exome chip genotyped data at the baseline examination. 
The ARIC study has been approved by the institutional review boards at each site, and 
written informed consent was obtained from all participating individuals.  
 
Measurements of Metabolites 
Metabolite profiling was completed in 2010 (batch 1) and 2014 (batch 2) using 
fasting serum samples that had been stored at -80°C since collection at the baseline 
examination. Batch 1 were all AAs and Batch 2 included both AAs (24.8%) and EAs 
(75.2%). In total, 602 metabolites were detected and semi-quantified by Metabolon (Durham, 
USA) using untargeted, gas- and liquid- chromatography-mass spectrometry (GC-MS and 
LC-MS)-based protocols (31, 32). To evaluate batch effects, a set of 97 samples were 
measured in both the 2010 and 2014 batches. There were 384 named metabolites that were 
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identified to be present in both batches and these metabolites will be used for this thesis 
research.  
In the present study, sample-level quality control was performed to remove 
individuals with missing values for more than 40% of the measured metabolites (1 sample 
was removed from batch 2). After sample-level quality control, metabolomic profiles were 
available in 2479 AAs and 1553 EAs. Exclusion criteria for metabolites includes: 1) six-there 
metabolites were excluded as more than 40% of the samples have missing values or values 
below the detection limit (BDL) within each batch; and 2) fifty metabolites were excluded as 
the Pearson correlation coefficient (r) between 2010 and 2014 measurements on the same 
stored sample (at least 46 out of the 97 pairs) is less than 0.30. Thus, this study was based on 
an evaluation of 271 named metabolites. Metabolite levels were analyzed as continuous 
variables, where missing/BDL values were imputed using random forest imputation based on 
the remaining observed measurements (33, 34). 
 
Genotypes 
Genotyping was performed with the Illumina HumanExome BeadChip v1.0 (“exome 
chip”) querying 247,870 single nucleotide variants (SNVs) at the baseline examination in 
11,071 EAs and 2,953 AAs in the ARIC study. The exome chip data was selected rather than 
sequence data that is also available in ARIC because using exome chip data maximizes the 
available sample size for this proposed analysis. To improve accurate calling of rare variants, 
genotyped data from ARIC along with 10 other studies from the Cohorts for Heart and Aging 
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Research in Genomic Epidemiology (CHARGE) Consortium were pulled together for joint 
calling, details were described elsewhere (35). A total of 8,994 variants were excluded after 
laboratory quality control steps, for instance call rate <95%, Hardy-Weinberg equilibrium 
test P value (pHWE) < 1×10-6, and poorly clustering variants (35). SNVs with missing rate 
>5% were removed from analysis.  
Exome chip variant annotation was completed using the Whole Genome Sequencing 
Annotation (WGSA) pipeline v055 (36), including dbNSFP v2.9 (37). Functional variants 
and genes were determined using ANNOVAR (38) according to the reference genome 
GRCh37/hg19 and National Center for Biotechnology Information RefSeq. 
 
Statistical Analyses 
Metabolite levels were winsorized (99%) within each batch, respectively. Due to 
right-skewed distributions of many metabolite levels, natural log transformation was applied 
to most metabolites prior to analyses. For metabolites that were still not normally distributed, 
a rank based inverse normal transformation was used. The transformation methods applied to 
each metabolite are provided in Appendix A- Supplemental Table 1. 
Race-specific exome-wide association studies for each metabolite level were 
conducted in men and women separately. Linear regression analyses were performed for the 
continuous metabolite levels. For common variants with MAF>5%, single variant association 
tests assuming an additive genetic model were conducted. Because our primary focus was on 
rare and low-frequency variants, we aggregated rare and low-frequency variants (MAF ≤ 
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5%) in groups based on a gene’s exons using burden tests (39). The unit-of-analysis is an 
annotated gene. All annotated coding variants, such as splicing, stop-gain, stop-loss, 
nonsynonymous, and indels within the gene were aggregated for the analysis. Genes with 
cumulative minor allele count < 3 within men or women of each race group were not 
analyzed. Models were adjusted for age and population substructure using the first three 
ancestry principal components (PCs) (40), with additional adjustment for estimated 
glomerular filtration rate (eGFR) and batch effects for metabolites. 
To test each SNV/gene and metabolite for difference of the effect size estimates for 
the SNV/gene calculated in the sex-specific analyses, we used an approximately normally 
distributed test statistic, Z (41). This Z test was selected as opposed to a sex-pooled 
multiplicative interaction test because traditional linear regression assumes homoscedasticity 
across all combinations of G and E which is often violated for rare variant burden test (42). 
𝑍 =
?̂?𝑚𝑒𝑛 − ?̂?𝑤𝑜𝑚𝑒𝑛
√𝑠𝑒(?̂?𝑚𝑒𝑛)2 + 𝑠𝑒(?̂?𝑤𝑜𝑚𝑒𝑛)2
 
We used AAs as the discovery sample and conducted replication in EAs. Using a 
false discovery rate (FDR) to correct for number of genes/SNV tested while considering the 
271 metabolites, we defined exome-wide significant genes/SNVs as those with FDR Q ≤ 5% 
in discovery AAs; these genes/SNVs were pursued for replication analyses in EAs. 
Replication was defined as those genes/SNVs with consistent directions of the effect, and 
FDR Q ≤5%, corrected for the number of genes/SNVs taken forward to evaluate in EAs. All 
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statistical analyses were conducted in R version 3.4 (R Foundation for Statistical Computing, 
Vienna, Austria). 
 
Results 
We conducted sex-specific exome-wide association analyses in 1292 women and 720 
men among ARIC AAs. A total of 827 EA women and 701 EA men were analyzed for 
replication. The baseline characteristics of both men and women in AAs and EAs were 
shown in Table II-1. The average age of women and men were comparable in both AAs 
(52.9 ± 5.6 vs. 53.0 ± 5.8 years) and EAs (54.3 ± 5.8 vs. 54.9 ± 5.8 years).  
 
Common single variant results 
Sex-stratified exome-wide association analysis identified and replicated (across race 
groups) common variants in 9 genes (ADA, ALMS1, DMGDH, DUSP11, FBX07, GCKR, 
KLKB1, LACTB, and VNN1) that were shown to be associated with metabolite traits in 
women. Common variants in the first four genes (ADA, ALMS1, DMGDH and DUSP11) 
were significant and replicated (across race groups) in men (Appendix A- Supplemental 
Table 2-3, Figure II-1). Eight out of the nine observed significant genes were consistent with 
those previously identified through analyses using pooled samples of men and women. One 
novel missense variant rs11555566 (ADA) with MAF ~6.2% - 7.8% was associated with N1-
methyladenosine in women (AA: ?̂? = 0.14 p = 2.44×10-11 FDR Q = 4.67×10-6, EA: ?̂? = 0.17 
  
22 
 
p = 7.55×10-5) and men (AA: ?̂? = 0.18 p=2.09×10-7 FDR Q = 0.04, EA: ?̂?=0.22 p=9.71×10-
6), respectively. 
In order to reveal sex–specific effects, we evaluated the estimated common genetic 
effects for heterogeneity between men and women. One common variant, rs3746414 
(ZFP64) showed a significant (p = 1.42×10-8, FDR Q = 0.05) difference between men and 
women for its association with propanediol in AAs. The significant association between 
rs3746414 and propanediol was only observed in AA men (?̂? = -0.30, p = 7.00×10-10). For 
AA women, the observed effect was positive but not significant (?̂? = 0.04, p = 0.22). 
Although we observed a similar difference in the direction of effects in EAs (negative effect 
in EA men and positive effect in EA women, data not shown), the sex-difference in genetic 
effects of rs3746414 on propanediol was not significantly replicated in EAs.  
 
Gene based rare and low-frequency variants 
For the gene-based approach, we report four known metabolite genes (ACAD8, 
CCBL1, ACY1 and DMGDH) that were successfully identified and replicated in female-only 
burden tests. The latter two (ACY1and DMGDH) pass the significance thresholds of 
identification and replication using male-only burden tests as well (Appendix A- 
Supplemental Table 4, Figure II-1). In the Z tests that evaluated the aggregated gene effects 
for heterogeneity between men and women, we observed significance (FDR Q<0.05) sex-
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difference in genetic effects of five genes on metabolites in AAs, however, none of them was 
successfully replicated in EAs (Appendix A- Supplemental Table 5). 
 
Discussion 
We performed sex-stratified exome-wide association analyses for 271 GC-MS/LC-
MS measured named metabolites in ARIC AAs, and identified a novel common variant 
rs11555566 in the ADA gene associated with N1-methyladenosine levels in both men and 
women. The association between rs11555566 and N1-methyladenosine levels was 
successfully replicated in independent samples of ARIC EA men and women, respectively. 
In AAs, we observed variants in 6 genes using common single variant tests or burden tests 
suggesting differed genetic effects on metabolite levels through testing for difference of 
effect sizes in sex-stratified results, although the difference between sexes was not shown to 
be consistent in an independent sample of EAs. 
In total, we identified and replicated variants in 12 genes through either common 
single variant analysis or gene-based burden test in sex-stratified analyses. Eleven of them 
were previously reported genes known to be associated with one or more metabolites in non-
sex-stratified genetic association studies (16, 19, 21, 22). Variants in 6 genes reached FDR-
corrected exome-wide significance for testing the difference of effects between men and 
women but we failed to replicate the sex differences in EAs. A previously reported sex-
specific genetic effect of a non-coding variant in CPS1 associated with glycine (26) was not 
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observed in our data. One difference between the analysis presented by Mittelstrass et al. (26) 
and that presented here is we focused on only coding functional variants in our analyses. 
In the results presented here, we identified a novel variant rs11555566 in the ADA 
gene to be association with N1-methyladenosine. ADA encodes the enzyme, adenosine 
deaminase that catalyzes the hydrolysis of adenosine to inosine and plays a critical role in 
purine metabolism and adenosine homeostasis (43, 44). The metabolite we observed to be 
associated with rs11555566, N1-methyladenosine, is one of the modified nucleosides that 
contains adenosine as its core base. N1-methyladenosine modification regulates transfer 
ribonucleic acid (tRNA) and messenger RNA (mRNA) stability (45, 46), and impacts a wide 
array of gene expression (47). Although ADA’s primary function is developing and 
maintaining the immune system in human (48), the metabolic basis and full physiological 
role of ADA is not completely understood. Evidence has been reported for a role of ADA in 
male fertility (49, 50). Our results suggest a slightly larger effect in men (?̂?=0.18, 0.22 in 
AAs and EAs, respectively) as compared to women (?̂?=0.14, 0.17 in AAs and EAs, 
respectively).  
There may be lack of consistency in testing sex differences of genetic effects between 
AAs and EAs due to: 1) the genetic architecture of the serum metabolome is consistent 
between men and women, and/or- 2) a lack of statistical power to detect small differences in 
genetic effects between men and women. Sex-stratified analyses followed by a z test testing 
for difference of effect sizes may not be powerful enough to test sex difference in genetic 
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effects on metabolome, particularly for rare and low-frequency genetic variants. Enhanced 
statistical methods and tools with sufficient power and flexibility for testing heterogeneity of 
genetics effects are needed. Finally, our study’s design with discovery in one race group and 
replication in another may not be ideal. The discovery sample for this study was AAs, a 
population with high level of genetic diversity to promote novel findings (51). However, the 
replication sample was EAs. Rare variants aggregated in genes may differ between the two 
races, and ancestry-specific rare variants may contribute to sex-specific effects on 
metabolites, which will not be consistent between races and missed in our analyses.  
In summary, we identified a novel variant in ADA associated with N1-
methyladenosine levels in both race groups, suggesting that sex-specific genetic effects of 
metabolites may exist. The lack of consistency in testing sex differences of the genetic 
effects between discovery and replication samples underscores that enhanced statistical 
methods and tools are warranted for further sex-specific effect studies. 
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Table II-1 Baseline characteristics of analyzed participants in the ARIC study 
 Women Men 
AAs EAs AAs EAs 
N 1292 827 720 701 
Age (years) 52.9 
(5.6) 
54.3 
(5.8) 
53.0 
(5.8) 
54.9 
(5.8) 
eGFR 
(mL/min/1.73 m²) 
105.5 
(18.6) 
92.0 
(14.9) 
101.2 
(17.8) 
90.5 
(14.2) 
AAs: African-Americans, EAs: European-Americans, eGFR: estimated glomerular filtration 
rate 
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Figure II-1 Significantly identified and replicated gene-metabolite pairs revealed by sex-
stratified exome-wide association studies.  
   
  
35 
 
 
 
CHAPTER III. RARE AND LOW-FREQUENCY GENETIC VARIANT × SEX 
INTERACTIONS IDENTIFY NOVEL LOCI INFLUENCING THE SERUM 
METABOLOME IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) 
STUDY 
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Abstract  
Metabolomic profiling and the integration of genomic data have proven to be 
powerful tools to investigate genetic effects underlying intermediate phenotype levels such as 
metabolites and may facilitate improved understanding of pathophysiologic processes of 
disease. However, most published studies did not consider sex as an effect modifier nor gene 
by sex interactions. The present study investigated rare and low-frequency genetic variants 
(minor allele frequency ≤ 5%) and sex interactions on serum metabolite levels and evaluated 
the joint effects of genetic main effects and gene-sex interactions. Chromatography-mass 
spectrometry measured metabolites and the Illumina HumanExome BeadChip genotyped 
exonic variants were analyzed in 2,012 African-Americans from the Atherosclerosis Risk in 
Communities (ARIC) study. Using gene-based rareGE and MiSTi approaches, we conducted 
exome-wide gene-sex interaction tests, and a joint analysis of genetic main and gene-sex 
interaction effects. Rare and low-frequency functional variants, (i.e. frameshift, 
nonsynonymous, stop/gain, stop/loss, and splicing) were aggregated by genes. Exome-wide 
significant genes (false discovery rate ≤ 5%) were evaluated for replication in an independent 
sample of 1,528 ARIC European-Americans. In total, we observed and replicated 14 gene-
metabolite associations through the joint test, 3 of which were novel, including PLA2G7- 
arachidonate (20:4n6), PTER- N-acetyl-beta-alanine and NPC2- leucylserine. The NPC2- 
leucylserine association arose from both genetic main effects and gene-sex interaction 
effects, as the interaction test using rareGE for NPC2-sex interaction on leucylserine levels 
reached nominal significance level (p = 3.79×10-04). In conclusion, this study applied 
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emerging statistical approaches to investigate the role of rare and low-frequency genetic 
variants and gene-sex interactions, and successfully identified novel genes associated with 
metabolites.  
Introduction 
Metabolomics is a scientific approach that systematically evaluates small-molecule 
metabolites in biologic samples that reflect the state of the system or whole organism and 
may provide additional insights into disease pathology (1-3). Both traditional genome-wide 
association studies (GWAS) and sequencing analyses across the exome or whole genome 
have successfully identified and verified hundreds of genetic loci associated with the levels 
of metabolites (4-16), and many of them can be further related to complex diseases or 
clinically relevant risk factors of disease development (12, 17).  
Sex-specific differences in metabolite patterns in healthy human have been reported 
in urine and plasma (18, 19), which suggests that sex should be considered further in 
metabolomic studies. Limited work has identified sex-specific metabolism-related genetic 
polymorphisms through sex-stratified GWAS and sex-specific pathway differences in the 
serum metabolome (20, 21). Additional systematic studies are needed to better understand 
the modifying effect of sex on the human metabolome and its genetic determinants with a 
particular focus on rare and low frequency (MAF ≤ 5%) variants. Rare and low frequency 
variants make up the vast majority of the genetic variation in the genome (22), and may 
account for part of the missing heritability along with gene-environmental (G×E) interactions 
(23).  
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Unlike well-established G×E interaction tests for common variants (24, 25), methods 
development for detecting rare variant G×E interactions is challenging because of relatively 
low power for a single marker test with MAF ≤5%, as well as inflated type 1 error rates and 
biased effect estimates for conventional burden tests (26). Emerging methods have been 
proposed to overcome these challenges. Su et al. proposed a novel and rigorous framework, 
Mixed effects Score Tests for interaction (MiSTi), to derive independent score statistics for 
fixed effects and the variance component that is more powerful to test G×E interaction terms 
of rare variants (27). A joint test that allows one to simultaneously test genetic main effects 
and interaction effects was proposed and successfully implemented by Chen and colleagues 
in the R package ‘rareGE’ (28).  
To date, there is no study systematically utilizing methods developed for testing rare 
variant G×E interactions in the setting of large-scale metabolomic data. In addition, an 
investigation of gene-sex interactions or sex-specific genetic variants related to metabolites 
has not been conducted in African-Americans (AAs). Therefore, in this study, we leveraged 
existing data from a large population-based multi-ancestry cohort, the Atherosclerosis Risk in 
Communities (ARIC) study that contains well-characterized AAs and European-Americans 
(EAs), to identify novel genetic loci influencing the serum metabolome that were not 
identified when considering the genetic main effect alone. 
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Methods 
Study Sample 
The ARIC study is a population-based prospective cohort study of 15,792 adults from 
four U.S. communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; 
and Washington County, MD), which has been described in detail previously (29). ARIC 
included both EAs and AAs aged 45-64 at the baseline examination (1987-1989). 
Participants completed three additional triennial follow-up examinations, a fifth exam in 
2011-2013, and a sixth exam in 2016-2017. There were 3,540 participants with complete 
metabolite measurements and exome chip genotyped data at the baseline examination. The 
ARIC study has been approved by the institutional review boards at each site, and written 
informed consent was obtained from all participating individuals.  
 
Measurements of Metabolites 
Metabolite profiling was completed in 2010 (batch 1) and 2014 (batch 2) using 
fasting serum samples that had been stored at -80° since collection at the baseline 
examination. Batch 1 were all AAs and Batch 2 included both AAs (24.8%) and EAs 
(75.2%). In total, 602 metabolites were detected and semi-quantified by Metabolon (Durham, 
USA) using untargeted, gas- and liquid- chromatography-mass spectrometry (GC-MS and 
LC-MS)-based protocols (30, 31). To evaluate batch effects, a set of 97 samples were 
measured in both the 2010 and 2014 batches. There were 384 named metabolites that were 
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identified to be present in both batches and these metabolites will be used for this thesis 
research.  
In the present study, sample-level quality control was performed to remove 
individuals with missing values for more than 40% of the measured metabolites (1 sample 
was removed from batch 2). After sample-level quality control, metabolomic profiles were 
available in 2,479 AAs and 1,553 EAs. Exclusion criteria for metabolites includes: 1) six-
there metabolites were excluded as more than 40% of the samples have missing values or 
values below the detection limit (BDL) within each batch; and 2) fifty metabolites were 
excluded as the Pearson correlation coefficient (r) between 2010 and 2014 measurements on 
the same stored sample (at least 46 out of the 97 pairs) is less than 0.30. After exclusions, this 
study was based on an evaluation of 271 named metabolites. Metabolite levels were analyzed 
as continuous variables, where missing/BDL values were imputed using random forest 
imputation based on the remaining observed measurements (32, 33). 
 
Genotypes 
Genotyping was performed with the Illumina HumanExome BeadChip v1.0 (“exome 
chip”) querying 247,870 single nucleotide variants (SNVs) at the baseline examination in 
11,071 EAs and 2,953 AAs in the ARIC study. The exome chip data was selected rather than 
exome or whole genome sequence data that is also available in ARIC because using exome 
chip data maximizes the available sample size for this analysis. To improve accurate calling 
of rare variants, genotyped data from ARIC along with 10 other studies from the Cohorts for 
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Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium were pulled 
together for joint calling, details were described elsewhere (34). A total of 8,994 variants 
were excluded after laboratory quality control steps, for instance call rate <95%, Hardy-
Weinberg equilibrium test P value (pHWE) < 1×10-6, and poorly clustering variants (34). 
SNVs with missing rate >5% were removed from analysis.  
Exome chip variant annotation was completed using the Whole Genome Sequencing 
Annotation (WGSA) pipeline v055 (35), including dbNSFP v2.9 (36). Functional variants 
and genes were determined using ANNOVAR (37) according to the reference genome 
GRCh37/hg19 and National Center for Biotechnology Information RefSeq. 
 
Statistical Analysis: 
Prior to the analyses, metabolite levels were winsorized (99%) within each batch. 
Each metabolite was investigated for its goodness-of-fit to normality. Due to right-skewed 
distributions of many metabolite levels, the natural log transformation was applied to most 
metabolites prior to analyses. For metabolites that are still not normally distributed, a rank 
based inverse normal transformation was used. The transformation methods applied to each 
metabolite were provided in Appendix B- Supplemental Table 1. 
Two analyses were conducted for each metabolite within each race group: 1) a joint 
analysis of genetic main effects and G×E interaction effects and 2) a G×E interaction term 
test only. The joint analysis was conducted using rareGE (28), and the interaction term test 
was conducted using both rareGE and MiSTi (27, 28). The unit-of-analysis is an annotated 
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gene. All annotated coding variants, such as splicing, stop-gain, stop-loss, nonsynonymous, 
and indels within the gene were aggregated for the analysis. Additionally, genes with 
cumulative minor allele counts ≤ 6 in each race were excluded. Models were adjusted for age 
and population substructure using the first three ancestry specific principal components (PCs) 
(38), with additional adjustment of estimated glomerular filtration rate (eGFR) and batch 
effects for metabolites. 
We used AAs as our discovery sample and conducted replication in EAs. Using a 
false discovery rate (FDR) to correct for number of genes tested while considering the 271 
metabolites, we defined exome-wide significant genes as those with FDR Q≤ 5% in 
discovery AAs; these genes were pursued for replication analyses in EAs. Replication was 
defined as those genes with FDR Q ≤ 5%, corrected for the number of genes taken forward to 
evaluate in EAs. All statistical analyses were conducted in R version 3.4 (R Foundation for 
Statistical Computing, Vienna, Austria). 
 
Results 
There was a total of 3,540 participants with measured metabolite levels and 
genotyped exome chip data in the ARIC study, including 2,012 AAs for discovery and 1,528 
EAs for replication. Women comprised more than half of the samples in both race groups 
(64.2% in AAs, 54.1% in EAs). In general, the average baseline age of AAs and EAs was 
comparable (AAs vs. EAs: 53.0 ± 5.7 vs. 54.6 ± 5.8 years), and AA participants tends to have 
slightly higher levels of eGFR (AAs vs. EAs: 104.0 ± 18.3 vs. 91.4 ± 14.6 mL/min/1.73 m²). 
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In AAs, we observed 48 gene-metabolite associations (FDR Q ≤ 5%) harboring rare 
and low-frequency variants through the joint analysis using rareGE (Appendix B- 
Supplemental Table 2). Distributions of QQ plots for joint test are shown in Appendix B- 
Supplemental Figure 1. Among them, 38 gene-metabolite associations were available in EAs, 
and these were taken forward for replication. In total, 14 gene-metabolite associations were 
successfully replicated using the joint test, 3 of which, namely PLA2G7- arachidonate 
(20:4n6), PTER- N-acetyl-beta-alanine and NPC2- leucylserine, were novel associations 
(Table III-1). The interaction term only test using rareGE for NPC2-sex interaction on 
leucylserine levels reached nominal significant (p = 3.79×10-04 -- 5.83×10-04 using 
random/fix effect interaction models (Table III-1), suggesting that gene-sex interaction 
effects contribute to the identified association between NPC2 and leucylserine levels. We 
additionally tested the marginal genetic main effect of these 14 gene-metabolite associations 
using SKAT test. The marginal genetic main effect of NPC2 on leucylserine levels reached 
nominal significance level (p = 1.07×10-03), which also suggesting that both the genetic main 
effects and the gene-sex interaction effects contribute to the identified joint effect. Genetic 
main effect for the rest of the genes showed similar p-values as results of the joint test (Table 
III-1). The rest of the identified gene-metabolite associations were mainly driven by genetic 
main effects (rareGE interaction test p > 0.05, Table III-1)  
Tests that focused on gene-sex interaction terms alone failed to identify any genes 
that passed the FDR corrected significance threshold using either rareGE or MiSTi. Using 
FDR Q < 0.2 as a suggestive significance threshold, six gene-metabolite pairs, 4 through 
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MiSTi and 3 through rareGE with 1 overlapping, were identified to be suggestive (Appendix 
B- Supplemental Table 3-4). Half of the genes had valid interaction test results in EAs, but 
the results were not replicated (p > 0.05 in EAs, Appendix B- Supplemental Table 3-4).   
 
Discussion 
To our knowledge, this is the first study to evaluate the role of rare and low frequency 
variants in gene-sex interactions and joint effects of genetic main and gene-sex interaction on 
metabolite levels. In total, we observed and replicated 14 gene-metabolite associations 
through the joint test, 3 of which were novel, including PLA2G7- arachidonate (20:4n6), 
PTER- N-acetyl-beta-alanine and NPC2- leucylserine. No significant novel loci were 
detected via analyzing the gene-sex interactions alone.  
Eleven of the 14 identified gene-metabolite pairs, comprised of 6 genes: ALMS1, 
ACY1, KLKB1, DMGDH, CCBL1, ACAD8, SLC25A45, and HAL, have been previously 
identified through either traditional GWAS or sequence-based genetic association studies that 
only considered genetic main effects (5, 6, 12-16). For example, rare loss-of-function 
variants in HAL, a gene that encodes histidine ammonia-lyase in the first step of histidine 
catabolism, was reported to be associated with increased histidine levels, and further linked 
to reduced incidence CHD risk (39). For these 6 known genes influencing metabolite levels, 
no evidence of gene-sex interactions were observed, suggesting that these gene-metabolite 
associations were not modified by sex.   
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Among the novel genes we identified through the joint test, PLA2G7 (Phospholipase 
A2 Group VII) was observed to be associated with arachidonic acid (20:4n6) in our data. 
Previous studies have reported several mutations in PLA2G7 associated with lipoprotein-
associated phospholipase A2 (Lp-PLA2) activity and mass, both positively and negatively 
(40-43). A large meta-analysis including 32 prospective studies by Thompson et al (44) 
showed that a reduction in Lp-PLA2 activity/mass was associated with reductions in risks of 
coronary heart disease and ischemic stroke. In addition, Lp-PLA2 activity has been recently 
approved by the FDA for routine clinical use to predict coronary heart disease events 
especially for black women (45). Phospholipase A2 (PLA2) catalyzes the hydrolysis of the 
sn-2 position of membrane glycerophospholipids to liberate arachidonic acid (46), the 
metabolite we observed and known for mediating inflammation (47). Therefore, the 
association we observed between PLA2G7 and arachidonic acid (20:4n6) is expected, and 
helps understanding the path of genetic variation in PLA2G7 to vascular inflammation and 
CVD.  
We also observed a novel association between PTER and N-acetyl-beta-alanine levels 
using the joint test. Previously GWAS has identified variants near PTER 
(phosphotriesterase-related) as a locus for obesity in European populations (48). The 
metabolite, N-acetyl-beta-alanine can be broken down to acetate and beta-alanine through 
hydrolysis, the latter of which forms carnosine (beta-alanyl-L-histidine), a dipeptide with 
anti-inflammatory, antioxidant, anti-glycation, and anti-ischaemic roles on cardiometabolic 
risk and disease (49). Current understanding of the protein encoded by PTER was limited to 
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hydrolase activity, acting on ester bonds. Our results provide insight into the molecular 
function or biological process that PTER may be involved, which may further link to 
cardiometabolic diseases. 
Out of the three novel gene-metabolite associations we identified and replicated 
through the joint test, NPC2- leucylserine also showed a contribution from gene-sex 
interaction effects. NPC2 (NPC Intracellular Cholesterol Transporter 2) encodes a protein 
that may function in regulating the transport of cholesterol through the late lysosomal system. 
In a recent genetic study of the human plasma proteome, common variants in NPC2 gene 
have been associated with levels of a blood protein, Cathepsin H (50), which is important in 
the overall degradation of lysosomal proteins. The NPC2 and NPC2-sex interaction 
associated metabolite in our data, leucylserine, is a dipeptide composed of leucine and serine. 
It is an incomplete breakdown product of protein digestion, which can be produced during 
lysosomal proteolysis. Although there is a lack of understanding the role of the NPC2-sex 
interaction on leucylserine levels, an animal study showed that in the ovary, NPC2 was 
restricted to steroidogenic cells that use cholesterol to produce hormones, and reported 
female infertility in NPC2 deficient mice (51). It is possible that sex hormones, for example 
estradiol, may be further related to lysosomal function (52) and are involved in protein 
catabolism that produces leucylserine.  
This study has several strengths. We used an emerging statistical approach that jointly 
tests the genetic main effect and gene-sex interaction on the human metabolome. Previous 
studies have shown that inclusion of G×E interactions may be important for identifying novel 
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signals, particularly for rare and low-frequency variants (53). Results in the present study 
support this conclusion by showing that novel genes were identified through this joint 
approach. Our study focused on the human metabolome, an intermediate phenotype that 
known to have larger genetic effects than clinical end points (5, 54), which are suitable to 
promote novel gene discoveries in the context of rare variant G×E interactions. Another 
strength of the present study is the joint calling of variants in a large pooled sample of studies 
conducted in the same laboratory, including the ARIC study. By increasing the sample size 
during the calling of variants, the ability to correctly call rare variants is enhanced (55).  
We successfully identified novel gene-metabolite associations, but the test that 
focuses on gene-sex interactions alone fail to reveal significant results for several reasons. 
First, sex may not modify the genetic effects on human metabolome, in other words, genetic 
architecture of the serum metabolome is largely consistent between men and women. Second, 
the study’s design having discovery in one race group and replication in another may not be 
ideal. The discovery sample for this study was AAs, a population with high level of genetic 
diversity to promote novel findings (56). However, the replication sample was EAs. Rare 
variants aggregated in genes may differ between two races, and ancestry-specific rare 
variants may contribute to sex-specific effects on metabolites, which will not be consistent 
between races and missed in our analyses. Finally, although we applied newly developed 
statistical methods that were known to have improved performance in testing G×E 
interactions (27, 28), future studies that focus on rare and low-frequency variants to identify 
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novel loci and G×E interactions may require much larger sample sizes than were available in 
just the ARIC study.  
In conclusion, this study applied emerging statistical approaches to investigate the 
role of rare and low-frequency variants in gene-sex interactions on the human metabolome, 
and successfully identified 3 novel genes associated with metabolites. Our results show 
promise for other larger scale studies analyzing rare variant GxE interactions to reveal novel 
biology. 
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Table III-1 Genes discovered and replicated through jointly testing the genetic main effects and gene-sex interactions in the ARIC 
study 
    African-Americans European- Americans 
Trait Gene Chr nSNP Main.p MiSTi.p Fix.int.p Ran.int.p Joint.p FDR-Q nSNP Main.p MiSTi.p Fix.int.p Ran.int.p Joint.p FDR-Q 
N-acetyl-1-
methylhistidine 
ALMS1 2 52 4.52×10-09 0.76 0.99 0.98 4.05×10-09 1.05×10-03 37 2.85×10-11 0.46 0.46 0.45 3.32×10-11 4.21×10-10 
aminooctanoate ALMS1 2 52 2.65×10-07 0.04 0.05 0.13 2.16×10-07 0.02 37 4.73×10-03 0.01 0.05 0.03 2.15×10-03 8.17×10-03 
N-acetyl-alanine ACY1 3 7 2.38×10-53 0.19 0.37 0.38 4.43×10-52 1.50×10-45 3 1.75×10-23 0.55 0.47 0.47 4.07×10-23 1.55×10-21 
N-acetyl-threonine ACY1 3 7 3.94×10-16 0.14 0.27 0.27 8.01×10-16 6.77×10-10 3 1.83×10-05 0.29 0.24 0.25 2.71×10-05 1.72×10-04 
N-acetyl-glycine ACY1 3 7 2.06×10-08 0.60 0.33 0.33 3.93×10-08 6.05×10-05 3 6.95×10-04 0.72 0.77 0.78 1.58×10-03 6.66×10-03 
leucylasparagine KLKB1 4 13 4.32×10-07 0.97 0.45 0.46 4.87×10-07 0.04 10 2.28×10-02 0.28 0.16 0.14 0.02 0.05 
dimethylglycine DMGDH 5 12 1.97×10-33 0.17 0.08 0.06 4.57×10-36 7.73×10-30 8 5.13×10-09 0.71 0.62 0.63 2.56×10-09 1.95×10-08 
arachidonate (20:4n6) PLA2G7 6 7 3.22×10-07 0.66 0.65 0.67 6.19×10-07 0.04 7 0.12 0.03 0.02 0.01 0.02 0.05 
indolelactate CCBL1 9 9 6.53×10-23 0.62 0.58 0.62 5.15×10-23 5.81×10-17 4 7.75×10-05 NA 0.34 0.30 2.70×10-04 1.47×10-03 
N-acetyl-betaalanine PTER 10 7 3.05×10-08 0.70 0.62 0.55 3.07×10-08 0.006 4 3.28×10-11 0.09 0.10 0.09 9.84×10-12 1.87×10-10 
isobutyrylcarnitine ACAD8 11 3 6.90×10-13 0.27 0.39 0.41 6.98×10-13 3.37×10-07 3 3.08×10-10 0.25 0.19 0.20 2.58×10-10 2.45×10-09 
deoxycarnitine SLC25A45 11 8 1.07×10-07 0.50 0.65 0.66 1.70×10-07 0.02 5 2.24×10-03 0.40 0.39 0.45 4.37×10-03 0.02 
histidine HAL 12 11 4.23×10-07 0.98 0.99 0.98 7.07×10-07 0.05 14 1.14×10-03 0.22 0.17 0.16 8.69×10-04 4.13×10-3 
leucylserine NPC2 14 4 1.07×10-3 - 5.83×10-04 3.79×10-04 1.93×10-07 0.02 5 2.79×10-03 0.08 0.03 0.07 6.78×10-03 0.02 
Main.p: p-value of genetic main effect from SKAT test; MiSTi.p: p-value of MiSTi interaction test; Fix.int.p: p-value of rareGE fixed 
effect interaction test; Ran.int.p: p-value of rareGE random effect interaction test; Joint.p: p-value of rareGE joint test; FDR-Q: false 
discovery rate Q-values of rareGE joint test
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CHAPTER IV. POWER OF TWO EMERGING METHODS FOR DETECTING 
AND CHARACTERIZING GENE×SEX INTERACTION EFFECTS FOR RARE 
VARIANT ANALYSES COMPARED TO STANDARD STRATIFIED ANALYSES 
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Abstract  
Although it is well known that complex diseases are influenced by both genetic and 
environmental factors, examples of validated gene by environment (G×E) interactions, especially 
for rare variants, are not common in epidemiological studies. One reason can be incomplete 
knowledge of the power of statistical methods used to search for rare variant G×E interactions in 
a given dataset. Improved understanding of the power of GxE interaction analyses may lead to 
better analysis and characterization of G×E interactions. We carried out a simulation study to 
investigate the performance of two newly developed methods, rareGE and MiSTi, that extend 
well-established common variant approaches in detecting rare variant gene-sex interaction 
effects on a quantitative phenotype. Compared with conventional burden tests, rareGE and 
MiSTi have superior performance in their power of identifying rare variant gene-sex interactions 
under a wide range of scenarios. Simulation results illustrate that an approach that jointly tests 
the genetic main effects and gene-sex interactions increases statistical power and has the 
potential to uncover novel genetic signals that have not been identified previously. In summary, 
use of simulated data for evaluation of the statistical power of emerging methods to detect rare 
variant G×E interactions shows an increase in statistical power for these newly introduced 
methods and justifies their use in practice.  
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Introduction 
Traditional genome-wide association studies (GWAS) have successfully identified a 
large number of loci associated with complex diseases and quantitative risk factor phenotypes. 
However, a large proportion of the heritability of these diseases/traits remains unexplained (1). 
Gene-environment (G×E) interactions, defined as different effects of a genotype on disease risk 
between differing environmental exposures (2, 3), and rare and low-frequency genetic variants, 
defined as variants with minor allele frequency (MAF) ≤5%, may both account for some of the 
unexplained heritability of complex disease-related phenotypes (4). 
Several large-scale genome-wide G×E studies have successfully identified novel loci 
accounting for the modifying effects of environmental exposures such as age, sex, BMI, alcohol 
consumption, and smoking status on cardiovascular disease (CVD) and its related intermediate 
traits (5-9). Studying G×E interactions involving rare variants may further extend our knowledge 
of the genetic architecture of complex traits and improve our understanding of the underlying 
mechanisms of common diseases (10-12). However, unlike well-established G×E interaction 
tests for common variants (13, 14), methods development for detecting rare variant G×E 
interactions is challenging for several reasons. First, considering typical sample sizes of most 
published GWAS studies, a single marker test is underpowered for rare and low frequency 
variants with MAF ≤5%. Second, conventional burden tests that simply summarize the total 
number of variants within a region and fit a model with this burden by environment interaction 
term, often result in inflated type 1 error rates and biased estimates when the genes and 
environment are not independent (i.e. G×E correlation) (15). 
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Recently developed novel approaches for testing rare variant G×E interaction effects (15-
20) face limitations. Jiao and colleagues (18, 19) treated genetic main effects as fixed effects, 
which may suffer from inflated type I error when the variants are rare (21). Lin et al proposed an 
interaction Sequence Kernel Association Test (15) that is powerful when both positive and 
negative directions of G×E effects exist, yet loses power when the variants in the set have the 
same direction of G×E effects. Tzeng et al. (16) assumed comparable magnitude of the variance 
component parameters for genetic main effects and G×E interactions, which may not be 
powerful if this assumption is not satisfied. Emerging methods have been proposed to overcome 
the aforementioned limitations. Su et al. proposed a novel and rigorous framework, Mixed 
effects Score Tests for interaction (MiSTi), to derive independent score statistics for fixed effects 
and the variance component, which is more powerful to test G×E interaction terms of rare 
variants (21). A joint test that allows one to simultaneously test genetic main effects and 
interaction effects and requires no assumption about the magnitude of the variance component 
parameters for the genetic main effects and G×E interactions was proposed and successfully 
implemented by Chen and colleagues in the R package called ‘rareGE’ (22). The former 
interaction-only test allows detecting G×E interactions regardless of the genetic main effect, 
while the latter joint testing approach aims to detect associated genetic effects allowing for gene-
environment interactions.   
Compared to common variant analyses, rare variant analyses often require a larger 
sample size to attain comparable power. Interaction analyses also need larger sample sizes in 
comparison with main effect analysis (23, 24). Therefore, interaction analyses for rare genetic 
variants require extra attention, particularly related to consideration of statistical power in studies 
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with a fixed sample size. In this chapter, we compared the performance and power of two 
emerging approaches “rareGE” (22) and “MiSTi” (21) with standard stratified analyses followed 
by a test of the differences of the effect sizes, “Z test”, (25) in simulation studies using real 
genotype data from European-Americans (EAs) in the Atherosclerosis Risk in Communities 
(ARIC) study. 
 
Methods- Simulation Studies 
“MiSTi” and “rareGE” have been shown to maintain a correct type I error rate under the 
null hypothesis (no G×E interactions) (21, 22). I evaluated and compared their power with the “Z 
test” for detecting rare variant gene-sex interactions under different scenarios assuming the gene 
variants and gene-sex interactions were associated with a quantitative phenotype (metabolite 
levels) but with varying effect sizes and directions of effects, as well as the total sample size. I 
also investigated the power of the rareGE joint test that allows one to simultaneously test genetic 
main effects and interaction effects in the aforementioned scenarios.  
 
Study Sample 
The ARIC study is a population-based prospective cohort study of 15,792 adults from 
four U.S. communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; and 
Washington County, MD), which has been described in detail previously (29). ARIC included 
both EAs and AAs aged 45-64 at the baseline examination (1987-1989). Participants completed 
three additional triennial follow-up examinations, a fifth exam in 2011-2013, and a sixth exam in 
2016-2017. There were 11,071 participants with exome chip genotyped data at the baseline 
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examination. The ARIC study has been approved by the institutional review boards at each site, 
and written informed consent was obtained from all participating individuals. 
 
Simulation Design 
Part 1. Detecting gene-sex interaction 
To evaluate the performance of the two emerging approaches and the conventional Z test 
in detecting gene-sex interaction, I first selected 10 genes having varying number of SNVs and 
pattern of linkage disequilibrium from the exome chip data genotyped in 11,071 EAs.  
For each gene, the modeled metabolite was generated with 500 replicates from, 
Y = 𝛽0 + 𝛽𝐸𝑠𝑒𝑥 + ∑ 𝛽𝑝
𝐺𝐺𝑝
𝑃
𝑝=1 + ∑ 𝛽𝑝
𝐺𝐸𝐺𝑝
𝑃
𝑝=1 𝑠𝑒𝑥 + 𝜀, where ε ~ N (0, 1) is a normal 
error term, β0 and βE was estimated from ARIC’s real data. For example, to generate glycine 
levels, the estimated β0 and βE from ARIC’s real data are β0 = 1.4, βE =0.6, and  
Glycine= 1.4 + 0.6*sex+∑ 𝛽𝑝
𝐺𝐺𝑝
𝑃
𝑝=1 + ∑ 𝛽𝑝
𝐺𝐸𝐺𝑝
𝑃
𝑝=1 (𝑠𝑒𝑥 − 0.5) + 𝜀 
The proportion of causal SNVs was set to 20% for each of the 10 genes. The effect size 
of non-causal SNVs was set to be zero. The effect size of the causal genetic main effect 𝛽𝑝
𝐺 was 
simulated under 2 settings: 
Setting 1. Randomly selected causal SNVs 𝛽𝑝
𝐺  ~ U(0,1), and 0 otherwise. 
Setting 2. 10% randomly selected causal SNVs 𝛽𝑝
𝐺 ~ U(0,1), and the betas for the other 
10% will be randomly selected causal SNVs 𝛽𝑝
𝐺 ~ U(-1,0), and 0 otherwise. 
Settings 1 and 2 simulated two extreme cases where genetic main effects favors burden 
(all in the same direction) and variance component (50% positive and 50% negative), 
respectively.  
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For each genetic main effect setting considered, the size of interaction effects was 
controlled by a constant c, which varied from 0.5, 1, 1.5 to 2, so that the power estimated under 
difference methods was discernible. I simulated 2 scenarios of gene-sex interactions: 
Scenario 1. 20% of randomly selected 𝛽𝑝
𝐺𝐸 = c, and 0 otherwise 
Scenario 2. 10% of randomly selected 𝛽𝑝
𝐺𝐸 = 𝑐, and 10% of randomly selected 𝛽𝑝
𝐺𝐸 = -c, 
and 0 otherwise 
Scenario 1 represented a moderate interaction effect scenario with 20% of the variants 
having the interaction effect in the same direction. Scenario 2 represented a moderate interaction 
effect with 20% variants having the interaction effect in opposite directions. The constant c was 
varied from 0.5, 1, 1.5, to 2 to evaluate the size of the interaction effect on power. The empirical 
power of each method under each scenario was calculated by comparing the resulting p-value to 
a cut-off value declaring statistical significance, α. I then calculated the proportion of times the 
null hypothesis was rejected (success rate) over the 500 replicates. I considered two α levels, one 
for nominal significance level p < 0.05, the other for exome-wide false discovery rate (FDR) < 
5%. Because I simulated metabolite levels based on variants within one gene each time and 
expected only one gene to be associated with the simulated phenotype across the exome, the 
FDR < 5% is equivalent to a Bonferroni corrected p < 4.95×10-6. 
 
Part 2. Effect of sample size on power 
To evaluate the effect of sample size on power, I doubled the exome chip data and then 
randomly selected subsets of the doubled genomic dataset to vary sample size from 20,000 down 
to 2,000. For this power simulation, I selected two scenarios when causal markers have main 
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effects in opposite directions (same as setting 2 of genetic main effects in part 1) and gene-sex 
interaction effects in the same direction and opposite directions (same as scenario 1 and 2 of 
interaction effects in part 1). To be specific, again using glycine as an example, the dataset was 
generated with parameters settings as below 
1.  Glycine= 1.4 + 0.6*sex+∑ 𝛽𝑝
𝐺𝐺𝑝
𝑃
𝑝=1 + ∑ 𝛽𝑝
𝐺𝐸𝐺𝑝
𝑃
𝑝=1 (𝑠𝑒𝑥 − 0.5) + 𝜀 
2. 20% of the SNVs within each gene are causal SNVs  
3. 10% randomly selected causal SNVs 𝛽𝑝
𝐺 ~ U(0,1), and the betas for the other 10% will be 
randomly selected causal SNVs 𝛽𝑝
𝐺 ~ U(-1,0), and 0 otherwise 
4.  
a. 10% of randomly selected 𝛽𝑝
𝐺𝐸 = 1, and 10% of randomly selected 𝛽𝑝
𝐺𝐸 = -1, and 
0 otherwise 
b.  20% of randomly selected 𝛽𝑝
𝐺𝐸 = 1, and 0 otherwise 
Step 3 generated 20% causal variants with genetic main effects in opposite directions. 
Step 4a represented a moderate interaction effect with 20% of the variants having the interaction 
effects in the opposite directions. 4b represented a moderate interaction effect with 20% variants 
having the interaction effects in the same direction. Following the same procedure as in part 1, 
the empirical power under different sample sizes was calculated by comparing the resulting p-
value to the significance level α (0.05 or 4.95×10-6) to determine success or failure and then 
computing the rate over 500 replicates. 
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Results 
Part 1. Performance in detecting gene-sex interaction 
The ten selected genes with varying number of SNVs and cumulative minor allele counts 
(cMAC) are presented in Table IV-1. The LD pattern for each of the selected genes is presented 
in supplemental figure 1. Rare and low-frequency variants aggregated in the selected genes are 
not in LD or in very low to moderate LD. The highest average LD observed is for the gene 
KIAA1551 (average LD < 0.1).  
Figure IV-1 shows the average power results across the 10 genes using the three methods 
with positive genetic main effects and two scenarios of interaction effects. Empirical power was 
calculated at the significance level of 0.05 and 4.95×10-6, respectively. The data shows a clear 
trend of increasing power with increasing effect sizes for the interaction effects and highlights 
that these two newly developed methods outperform the conventional Z test under each situation 
investigated here. Notably, at exome-wide significance, even these newly developed methods for 
testing interaction effects are greatly underpowered (less than 50% power) for a sample size of 
11,000, while the joint test of genetic main effects and gene-sex interaction effects has a nearly 
70% power for the same sample size with a modest genetic main effect we simulated. The data 
presented in Figure IV-1 shows that MiSTi is a more powerful test than rareGE when the causal 
markers have interaction effects in the same direction. They also suggest that the rareGE random 
effect interaction test has the highest power when the causal markers have interaction effects in 
opposite directions, which agrees with our prior expectation; the SKAT-type tests are most 
powerful when causal markers have interaction effects in opposite directions. Both MiSTi and 
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rareGE showed a substantial higher power than the Z test in each scenario as demonstrated in 
Figure IV-1 .  
We then examine factors that influenced the performance of each methods in each of the 
10 genes, including, 1) number of SNVs and cMAC within each gene; 2) effect size of the 
interaction effects; 3) causal markers within a gene having gene-sex interaction effects in the 
same vs opposite directions; 4) genetic main effects of causal markers in the same vs opposite 
directions. The power results are presented at the significance levels of 0.05 and Bonferroni 
corrected 4.95×10-6 and the average power across the 10 genes are summarized in Table IV-2 
and accompanying Figures. Figure IV-2 shows that power increases with increasing number of 
SNVs and cMAC aggregated within each gene. Comparing Figure IV-3 to Figure IV-2 shows 
that the power increases with increasing interaction effect size for each gene (Figure IV-3 gene-
sex interaction effect c = 2 vs. Figure IV-2 gene-sex interaction effect c = 1). MiSTi appears to 
be slightly more powerful than the rareGE fixed effect interaction test for most genes, which is 
consistent with the results observed for the average power across the 10 genes (Figure IV-1 ). 
Figure IV-4 shows the power when causal markers within a gene have interaction effects in 
opposite directions, and demonstrates that both newly developed interaction test methods are 
superior than the Z test when the causal markers have interaction effects in different directions. 
Under such a scenario, the rareGE random effect test has the highest power to test interaction 
effects for most genes, which again matches our expectation. Compared to Figure 4b, Figure 
IV-5 suggests that that the power remains almost the same no matter whether the causal markers 
have the same or different directions of main effects except that the Z test was the least powerful 
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under the situation that causal markers have different directions of both genetic main effects and 
interaction effects. 
 
Part 2. Effect of sample size on power 
Figure IV-6 shows the average power results across 10 genes using the three methods 
with genetic main effects in opposite directions, and interaction effects in either the same 
direction or opposite directions considering sample size varying from 2000, 5000, 10000, 15000 
to 20000. Empirical power was calculated at the significance levels of 0.05 and 4.95×10-6, 
respectively. Figure IV-6 shows a clear trend of increasing power with increasing sample size 
and demonstrates that the two newly developed methods, rareGE and MiSTi consistently 
outperforms the conventional Z test, but are still greatly underpowered (40%) to detect an 
exome-wide significance G×E interaction with modest effect size 1 in a sample size of 20,000. 
Figure 6a and 6b show the power when causal markers have interaction effects in opposite 
directions, and supported our results in part 1 that rareGE random effect test has the highest 
power to test interaction effects in such scenario, although the difference between the power of 
rareGE random effect test and MiSTi is small. Similarly, Figure 6c and 6d again show that 
MiSTi is a more powerful test than rareGE when the causal markers have interaction effects in 
the same direction regardless of varied sample size. For the rareGE joint test that simultaneously 
considers genetic main effects and interaction effects, the sample size required to detect a gene at 
nominal significance level with 80% power would be greater than 10,000 using the simulated 
effect sizes based on real data. To detect a gene at exome-wide significance level with sufficient 
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power, an even larger sample size (> 20,000) will be required for the effect sizes considered 
here.  
 
Discussion 
In this chapter, we compared three methods, rareGE, MiSTi and a conventional Z test, 
and evaluated their power in detecting gene-sex interaction effects as well as jointly testing for 
genetic main effects and gene-sex interaction effects. We show that, 1) both rareGE and MiSTi 
tests are more powerful than the conventional Z test in detecting gene-sex interaction effects, in 
the context of rare genetic variants analysis; 2) rareGE joint test is the most powerful when both 
genetic main effect and gene-sex interaction are present, and the power increases with increasing 
effect sizes for the interaction effects. 
Compared with a conventional Z test of the interaction effects, rareGE and MiSTi tests 
have higher power for the simulated situations considered here, especially when causal genetic 
markers have different directions of gene by environment interaction effects. When causal 
markers have gene by environment interaction effects in the same direction, MiSTi slightly 
outperforms rareGE because rareGE is a SKAT-type test and suffers loss of power in such 
scenario (15, 22, 26). In contrast, when causal markers have gene by environment interaction 
effects in opposite directions, rareGE outperforms MiSTi, because in this scenario the interaction 
effect model favors the variance component, which is the scenario that a SKAT-type test have 
the greatest power (27). The rareGE joint test that simultaneously tests genetic main effects and 
interaction effects is generally more powerful across the simulated scenarios considered here, 
suggesting that a joint test is an attractive approach for testing genetic associations allowing for 
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G×E interactions when genetic main effects exist (28). Using this joint test, the results show that 
we have sufficient power to detect a gene with moderate effect size at nominal significance level 
with a sample size of 10000. However, no matter what methods is used, a much larger sample 
size is required to detect exome-wide significant genes.    
We applied the rareGE and MiSTi approaches from Chapter 3 of this dissertation using 
real data compromising 271 measured and named metabolites and exome chip data genotyped in 
3,540 African-Americans (AAs) and EAs from the ARIC study. We identified and replicated 14 
gene-metabolite pairs through joint test, including 3 novel associations. There was no exome-
wide significant gene-sex interaction using either rareGE or MiSTi approach. The real data 
results are in line with our simulation results for power: these two newly developed methods are 
underpowered to detect an exome-wide significance G×E interaction under the sample sizes 
available in the ARIC study. We successfully detected a few novel genes associated with 
metabolites through the joint test, likely because the genetic main effects on metabolites are 
normally much larger than that for disease or disease risk factor levels (29, 30).   
The present simulation study has some limitations. We considered only two extreme 
situations, causal genetic variants with G×E interaction effects all in the same direction or 
completely in opposite directions. In practice, the directions of causal genetic variants with G×E 
interaction effects contributing to complex diseases are most likely a mixture of the two 
scenarios. Also, in practice, the proportion of causal variants in a gene may not be 20% as we 
simulated. In addition, we did not consider multiple genes simultaneously; the quantitative 
phenotype was simulated based on effects of genetic variants within one gene. Under a polygenic 
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scenario, the power of testing a particular G×E interaction may be affected by other genetic main 
effects or interactions.  
In conclusion, we have shown in the context of rare genetic variants that utilizing 
emerging statistical methods for detecting G×E interactions leads to an increase in power. The 
approach of jointly testing the genetic main effects and G×E interactions for rare variants has the 
potential to detect novel genes associated with a phenotype of interest. Our simulations justify 
their use in practice and provide guidance on sample size needed under various scenarios. 
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Table IV-1 Characteristics of the 10 selected genes in European- Americans from the ARIC 
exome chip data 
Gene CHR nSNV nSNVused cMAC 
SEMG1 20 12 8 275 
LIPG 18 12 11 338 
NEFM 8 14 13 668 
ANKS3 16 20 14 1482 
SLC26A4 7 27 21 349 
SYCP2 20 29 17 2899 
WDR17 4 32 28 1106 
KIAA1551 12 42 31 258 
CELSR3 3 54 41 845 
COL6A3 2 92 77 2111 
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Table IV-2 Power of various methods under scenarios with 2 settings of genetic main 
effects (setting 1 genetic main effects in the same direction and setting 2 genetic main 
effects in opposite directions) and two scenarios of interaction effects (GxE effects in the 
same direction and GxE effects in opposite directions), respectively. The significance levels 
α are 0.05, and bonferroni corrected 4.95×10-6, respectively. 2a. the size of interaction 
effect c=0.5; 2b. the size of interaction effect c=1; 2c. the size of interaction effect c=1.5; 
2d. the size of interaction effect c=2. 
 
 
Table 2a. 
Alpha 
levels 
Methods GxE same direction c=0.5 GxE opposite direction 
c=±0.5 
Setting 1 Setting 2 Setting 1 Setting 2 
0.05 MiSTi 0.395 0.403 0.355 0.357 
rareGE 0.396 0.393 0.387 0.384 
Z test 0.329 0.347 0.259 0.254 
Joint 0.702 0.678 0.682 0.668 
4.95×10-
6 
MiSTi 0.158 0.165 0.137 0.137 
rareGE 0.157 0.164 0.151 0.149 
Z test 0.456 0.084 0.038 0.041 
Joint 0.077 0.434 0.434 0.427 
 
 
Table 2b. 
Alpha 
levels 
Methods GxE same direction c=1 GxE opposite direction c=±1 
Setting 1 Setting 2 Setting 1 Setting 2 
0.05 MiSTi 0.578 0.579 0.507 0.513 
rareGE 0.558 0.565 0.542 0.553 
Z test 0.490 0.498 0.365 0.371 
Joint 0.785 0.768 0.762 0.759 
4.95×10-
6 
MiSTi 0.332 0.331 0.300 0.299 
rareGE 0.331 0.329 0.320 0.325 
Z test 0.245 0.250 0.187 0.186 
Joint 0.569 0.546 0.549 0.536 
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Table 2c. 
Alpha 
levels 
Methods GxE same direction 
c=1.5 
GxE opposite direction 
c=±1.5 
Setting 1 Setting 2 Setting 1 Setting 2 
0.05 MiSTi 0.693 0.690 0.604 0.618 
rareGE 0.672 0.667 0.650 0.657 
Z test 0.599 0.600 0.433 0.442 
Joint 0.838 0.822 0.819 0.814 
4.95×10-
6 
MiSTi 0.442 0.447 0.392 0.396 
rareGE 0.422 0.425 0.410 0.412 
Z test 0.336 0.337 0.249 0.250 
Joint 0.642 0.629 0.623 0.618 
 
 
Table 2d. 
Alpha 
levels 
Methods GxE same direction c=2 GxE opposite direction c=±2 
Setting 1 Setting 2 Setting 1 Setting 2 
0.05 MiSTi 0.753 0.756 0.677 0.689 
rareGE 0.742 0.732 0.719 0.727 
Z test 0.673 0.678 0.505 0.494 
Joint 0.862 0.854 0.851 0.850 
4.95×10-
6 
MiSTi 0.525 0.531 0.454 0.464 
rareGE 0.487 0.498 0.483 0.492 
Z test 0.397 0.405 0.297 0.286 
Joint 0.701 0.680 0.678 0.674 
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Figure IV-1 Power of three methods with positive genetic main effects and two scenarios of 
interaction effects (1a & 1c. GxE in the same direction; 1b & 1d. GxE in 
opposite directions). The significance threshold for 1a & 1b is Bonferroni 
corrected (4.95×10-6), for 1c & 1d is 0.05. 
 
 
GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05 
significance threshold; MiSTi.bonf/MiSTi05: the power of MiSTi interaction test under 
Bonferroni corrected/0.05 significance threshold; GErandom.bonf/GErandom05: the power 
of rareGE random effect interaction test under Bonferroni corrected/0.05 significance 
threshold; Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni 
corrected/0.05 significance threshold 
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Figure IV-2 Power of three methods with genetic main effects in both directions and gene-
sex interaction effects in the same direction (c=1). The significance threshold for 
2a is 0.05 for 2b is Bonferroni corrected 4.95×10-6. 
 
Figure 2a.                                                                   Figure 2b.  
 
GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05 
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under 
Bonferroni corrected/0.05 significance threshold; GEfix.bonf/GEfix05: the power of rareGE 
fix effect interaction test under Bonferroni corrected/0.05 significance threshold; 
Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni corrected/0.05 
significance threshold; cMAC: cumulative minor allele counts 
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Figure IV-3 Power of three methods with genetic main effects in both directions and gene-
sex interaction effects in the same direction (c= 2). The significance threshold 
for 3a is 0.05 for 3b is Bonferroni corrected 4.95×10-6. 
 
Figure 3a.                                                                   Figure 3b. 
GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05 
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under 
Bonferroni corrected/0.05 significance threshold; GEfix.bonf/GEfix05: the power of rareGE 
fix effect interaction test under Bonferroni corrected/0.05 significance threshold; 
Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni corrected/0.05 
significance threshold; cMAC: cumulative minor allele counts 
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Figure IV-4  Power of three methods with genetic main effects and gene-sex interaction 
effects in different directions (c = ±2). The significance threshold for 4a is 0.05 
for 4b is Bonferroni corrected 4.95×10-6. 
Figure 4a.                                                               
Figure 4b. 
 
GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05 
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under 
Bonferroni corrected/0.05 significance threshold; GErandom.bonf/GErandom05: the power 
of rareGE random effect interaction test under Bonferroni corrected/0.05 significance 
threshold; Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni 
corrected/0.05 significance threshold; cMAC: cumulative minor allele counts 
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Figure IV-5 Power of three methods with genetic main effects in the same direction and 
gene-sex interaction effects in different directions (c = ±2). The significance 
threshold is Bonferroni corrected 4.95×10-6. 
 
GEjoint.bonf: the power of rareGE joint test under Bonferroni corrected significance 
threshold; Fisher.bonf: the power of MiSTi interaction test under Bonferroni corrected 
significance threshold; GErandom.bonf: the power of rareGE random effect interaction test 
under Bonferroni corrected significance threshold; Ztest.bonf: the power of the conventional 
Z test under Bonferroni corrected significance threshold; cMAC: cumulative minor allele 
counts 
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Figure IV-6 Power comparisons of three methods with genetic main effects in opposite 
directions and two scenarios of interaction effects (6a & 6b. GxE in opposite 
directions c = ±1; 6c & 6d. GxE in the same direction c = 1) under different 
significance thresholds and varied sample size.  
6a. α= 0.05                                          6b. α= 4.95×10-6 
 
6c. α= 0.05                                         6d. α= 4.95×10-6 
 
GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05 
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under 
Bonferroni corrected/0.05 significance threshold; GErandom.bonf/GErandom05: the power 
of rareGE random effect interaction test under Bonferroni corrected/0.05 significance 
threshold; Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni 
corrected/0.05 significance threshold; cMAC: cumulative minor allele counts 
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CHAPTER V. SYNTHESIS 
 
This dissertation utilized metabolomic profiling and exome chip data to evaluate sex-
specific genetic effects and gene-sex interactions on the serum metabolome with a particular 
focus on rare and low-frequency (minor allele frequency ≤ 5%) genetic variants (Chapter 2-
3). The study participants included both African-Americans (AAs) and European-Americans 
(EAs) belonging to the large population-based Atherosclerosis Risk in Communities (ARIC) 
study. A simulation study (Chapter 4) was conducted to evaluate the power of three different 
methods for testing rare variant gene-sex interactions, and the results of this simulation study 
served as a justification of the analyses performed in Chapters 2 and 3. Overall, several 
genetic variants, either common genetic variants or rare and low-frequency variants 
aggregated within a gene, were identified to be significantly associated with metabolite 
levels. These findings underscore challenges and opportunities for identifying gene by 
environment (G×E) interactions and novel genetic loci by taking into account environmental 
factors and may lead to better understanding of disease. 
 
Summary of results 
In Chapter 2, we performed a sex-stratified exome-wide association study for 271 
GC-MS/LC-MS measured named metabolites in ARIC AAs, and pursued replication in an 
independent sample of ARIC EA men and women. . A novel common variant, rs11555566, 
in the ADA gene was associated with N1-methyladenosine levels, which was successfully 
identified and replicated in both men and women in both race groups. The results suggested a 
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larger effect of rs11555566 in men (estimated effect 0.18-0.22) as compared to women 
(estimated effect 0.14-0.17), but the difference was not statistically significant. In addition, 
we observed variants in 6 genes using common single variant tests or burden tests suggesting 
differing genetic effects on metabolite levels through testing for difference of the effect size 
estimates in sex-stratified results. However, the difference between the sexes was not shown 
to be consistent in an independent sample of ARIC EAs. This study suggests that sex-specific 
genetic effects of metabolites may exist, but the lack of consistency in testing sex differences 
of the genetic effects between discovery and replication samples underscores that future 
studies should consider sex-specific effects with improved (i.e. more powerful in the setting 
of rare variants) statistical methods and tools. Accordingly, we conducted an exome-wide 
gene-sex interaction study using emerging statistical methods, rareGE and MiSTi in Chapter 
3. To our knowledge, this is the first large-scale study to evaluate the role of rare and low 
frequency variants in gene-sex interactions and joint effects of genetic main and gene-sex 
interaction on metabolite levels. In total, we observed and replicated 14 gene-metabolite 
associations through the joint test, 3 of which were novel, including PLA2G7- arachidonate 
(20:4n6), PTER- N-acetyl-beta-alanine and NPC2- leucylserine. No significant novel loci 
were detected via analyzing gene-sex interactions alone. Although we applied newly 
developed statistical methods that were known to have improved performance in testing G×E 
interactions (48, 49), studies that focus on rare and low-frequency variants to identify novel 
loci and G×E interactions may require much larger sample size than that available in this 
dissertation research. 
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In Chapter 4, we compared three methods, rareGE, MiSTi and the conventional Z 
test, and evaluated their power in detecting gene-sex interaction effects as well as jointly 
testing for genetic main effects and gene-sex interaction effects. We illustrate that: 1) 
compared with the conventional Z test, rareGE and MiSTi have superior performance in their 
power of identifying rare variant gene-sex interactions under a wide range of scenarios, and 
2) the rareGE joint test is most powerful when both genetic main effect and gene-sex 
interaction are present, and the power increases with increasing effect sizes for the interaction 
effects, which demonstrates the potential to uncover novel genetic signals that have not been 
identified previously. 
Previous studies of the association between genetic variants and metabolite levels 
rarely considered sex as a potential effect modifier. These studies identified numerous 
genetic loci associated with one or multiple metabolite levels (73-85). In contrast to previous 
efforts, this dissertation is devoted to evaluating possible sex-specific common genetic 
effects and the role of rare and low-frequency genetic variants on the serum metabolome 
while taking into account sex effects. My results identified several novel genetic variants 
influencing the human metabolome, and the rigor of these findings was established through 
significant discovery in AAs and successful replication in EAs from the ARIC study. Sex-
specific genetic effects and gene-sex interaction effects have been shown to contribute to the 
observed novel gene-metabolite associations. Our results demonstrate increased power from 
using emerging statistical methods for detecting gene-sex interactions and show promise for 
other larger scale studies analyzing rare variant GxE interactions to reveal novel biology. 
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Strength and Limitations 
This dissertation takes full advantage of available data in the large multi-ethnic ARIC 
study to explore sex-specific genetic effects and gene-sex interactions with a focus on rare 
and low-frequency genetic variants on the metabolome using multiple statistical approaches. 
The genetic variants of the exome chip data in the ARIC study were jointly called in a larger 
pooled sample of studies conducted in the same laboratory, including the ARIC study. By 
increasing the sample size during the calling of variants, the ability to correctly call rare 
variants is enhanced (94), which facilitate the identification of novel genetic variants. In 
addition to the conventional Z test that tests the difference of the effect size estimates from 
sex-stratified analyses, we applied emerging statistical approaches for rare variant gene-sex 
interactions and jointly tested for genetic main effects and gene-sex interactions on the 
human metabolome. Previous studies have shown that inclusion of G×E interactions is 
important in terms of identifying novel signals, particularly for rare and low-frequency 
variants (38). Results in the present study supported this conclusion by showing that novel 
genes were identified through the joint approach.  
Limitations of the present dissertation warrant consideration. There are several 
reasons that may have caused lack of consistency in testing sex differences of the genetic 
effects between AAs and EAs. First, it may be that sex does not modify the genetic effects on 
the human metabolome. In other words, the genetic architecture of the serum metabolome is 
consistent between men and women. Second, the study design involved discovery in one race 
group and replication in another and this may not be ideal. The discovery sample for this 
study was AAs, a population with high level of genetic diversity to promote novel findings 
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(95). However, the replication sample was EAs. Rare variants aggregated in genes may differ 
between the two race groups, and ancestry-specific rare variants may contribute to sex-
specific effects on metabolites, which will not be consistent between races and missed in our 
analyses. Further studies with discovery and replication samples in an ancestry-specific 
manner followed by a trans-ancestry meta-analysis will have the advantage of discovering 
ancestry-specific rare and low-frequency genetic variants and provide evidence of trans-
ancestry loci. Finally, we established that there was likely lack of statistical power to detect 
exome-wide rare and low-frequency genetic variant gene-sex interactions in our studies. 
Through simulation studies and application in real data, we demonstrated that both sex-
stratified analyses followed by a Z test testing for difference of the effect size estimates and 
current statistical methods in detecting G×E interaction effects were not powerful enough to 
detect small to moderate sex difference in genetic effects on the metabolome. Improved 
statistical methods and tools with sufficient power and flexibility for testing G×E interactions 
are warranted, as well as collaborations across different studies to increase sample size.  
 
Future Directions 
The results described above need follow-up studies to better understand underlying 
biological processes giving rise to the observed associations and to establish potential links to 
disease. Follow-up investigations, such as experimental animal studies, of the genes 
identified in the context of interactions with sex or sex-stratified analyses are likely to 
provide new insights into the understanding of gene functions and biochemical changes in 
men and women. Researchers using genetically modified mice have revealed significant sex 
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differences in the development of cardiovascular phenotypes. In many of the models, cardiac 
pathological phenotypes were developed in male, but not in female mice as summarized by 
Du et al (96). For example, genetic deletion of the peroxisome proliferator-activated receptor 
alpha (PPARalpha), a gene involved in cellular lipid utilization, caused cardiac lipid 
accumulation, hypoglycemia and death in all male, but only 25% of female mice (97). In 
another study, the generated transgenic HDAC5S/A mice overexpressed histone deacetylase 
(HDAC) in cardiomyocytes which caused death in male but not in female mice (98). 
The genetic markers identified in this dissertation may be used in future studies for 
association with disease risk. Previous studies have identified different genetic variants 
influencing CVD risk in a sex-specific manner (12, 13, 99, 100). Using identified genetic 
factors to construct genetic risk scores has been demonstrated to provide powerful and robust 
CVD risk prediction beyond traditional risk factors (101-103). Given these findings, 
improved genetic risk profile from sex-specific genetic markers is expected to further 
facilitate disease risk prediction.  
Metabolomic profiles provide significant insights into biological and 
pathophysiological pathways that may be altered during the development and progression of 
diseases. However, metabolomic profiling performed from serum may not inform us about 
organ-specific pathophysiological processes. For complex diseases such as CVD, molecular 
changes occur within the large artery wall or liver may be more informative compared to that 
provided by serum. Future metabolomic studies at the organ level may supplement the 
measurements of changes in metabolites in serum samples and shape our understanding of 
metabolism. On the other hand, a recent study of metabolomic signatures of Alzheimer 
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disease (AD) using both brain tissue and blood samples has showed a metabolite class, 
sphingolipids that were consistently associated with severity of AD pathology in brain and 
AD progression across prodromal and preclinical stages in blood. 
During the course of this dissertation, I witnessed two changes to the field of human 
genetics First, the transition from GWAS to whole genome sequencing studies. Second, the 
introduction of large sample sizes in a single study, such as the Million Veteran Program 
(104) and the United Kingdom Biobank (105). These changes offer both opportunities and 
challenges to researchers doing genetic analysis. Appropriate analytical approaches are a 
continued concern in genetic studies of complex disease. There are multiple challenges, for 
examples: how to identify causal genetic variants beyond associations; how to appropriately 
and informatively incorporate environmental factors; and how to improve the computational 
speed to satisfy the need of handling big data. Utilizing metabolomic data requires additional 
analytical techniques to properly account for highly correlated metabolite levels. Developing 
novel statistical methods such as machine learning approaches for high dimensional data will 
benefit future studies to advance precision medicine through integrating multi-omics data.  
Most genetic studies of metabolomics focus on genetic main effects. In this 
dissertation, the analyses were extended to G×E interactions. However, only interactions with 
sex were tested. This was because sexual dimorphism in metabolites has been previously 
observed (87, 106), sex is easy to measure, and a balanced division between sexes may lead 
to greater statistical power to discover novel loci. Work on rare variants and interactions with 
other environmental exposures (e.g., alcohol and smoking) should be done to improve 
understanding and uncover additional genes associated with metabolite levels, refine known 
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disease loci, or reveal the underlying biology mechanism influenced by both genetic variants 
and environmental factors. Because of limited statistical power, we have shown that most 
interactions of rare and low-frequency genetic variants with environment factors cannot be 
identified or replicated on a genome-wide scale. One way to ease this problem is to restrict to 
the metabolites that were previously linked to genetic variants and environment factors, 
which will reduce the multiple-testing burden for analyses. Another way is to pool or meta-
analyze metabolomic and genomic measurements from multiple studies together to have a 
much larger number of individuals than represented here. It is clear that G×E interaction 
studies would have an increased power by increasing the size of the discovery sample (107, 
108). 
 
Conclusions 
This dissertation work suggests new evidence about sex-specific genetic influences 
on the human metabolome and reports novel genetic variants that were not previously 
identified when gene-sex interaction effects were omitted in previous studies. Additionally, 
this dissertation provides insights into the power and desired sample size in conducting rare 
variant G×E interaction studies under various scenarios, which facilitate the understanding of 
current G×E interaction results and show promise for future large-scale studies utilizing G×E 
interactions to investigate the genetic and environmental factors of disease etiology. 
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APPENDICES 
Appendix A. supplemental materials for Chapter 2 
Supplemental Table 1. List of 271 metabolites and transformation methods applied 
Metabolites Super_Pathway Sub_Pathway Platform Transformation 
alanine Amino Acid Alanine and Aspartate Metabolism LC/MS Pos rank based inverse normal 
asparagine Amino Acid Alanine and Aspartate Metabolism LC/MS Pos rank based inverse normal 
aspartate Amino Acid Alanine and Aspartate Metabolism LC/MS Polar rank based inverse normal 
N-acetylalanine Amino Acid Alanine and Aspartate Metabolism LC/MS Neg natural log 
creatine Amino Acid Creatine Metabolism LC/MS Pos rank based inverse normal 
creatinine Amino Acid Creatine Metabolism LC/MS Pos rank based inverse normal 
glutamate Amino Acid Glutamate Metabolism LC/MS Pos natural log 
pyroglutamine Amino Acid Glutamate Metabolism LC/MS Pos rank based inverse normal 
5-oxoproline Amino Acid Glutathione Metabolism LC/MS Neg not transformed 
betaine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos not transformed 
dimethylglycine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos natural log 
glycine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos natural log 
N-acetylglycine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Neg rank based inverse normal 
N-acetylthreonine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Neg natural log 
serine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos rank based inverse normal 
threonine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos rank based inverse normal 
4-guanidinobutanoate Amino Acid Guanidino and Acetamido Metabolism LC/MS Pos natural log 
3-methylhistidine Amino Acid Histidine Metabolism LC/MS Neg rank based inverse normal 
histidine Amino Acid Histidine Metabolism LC/MS Neg rank based inverse normal 
N-acetyl-1-methylhistidine Amino Acid Histidine Metabolism LC/MS Pos natural log 
trans-urocanate Amino Acid Histidine Metabolism LC/MS Pos natural log 
2-methylbutyrylcarnitine (C5) Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
3-hydroxyisobutyrate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Polar natural log 
3-methyl-2-oxovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
alpha-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
beta-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
beta-hydroxyisovaleroylcarnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
isobutyrylcarnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
isoleucine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
isovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
isovalerylcarnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
leucine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
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tiglyl carnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
valine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
glutarate (pentanedioate) Amino Acid Lysine Metabolism LC/MS Polar rank based inverse normal 
glutarylcarnitine (C5) Amino Acid Lysine Metabolism LC/MS Pos rank based inverse normal 
lysine Amino Acid Lysine Metabolism LC/MS Polar rank based inverse normal 
N6-acetyllysine Amino Acid Lysine Metabolism LC/MS Pos rank based inverse normal 
pipecolate Amino Acid Lysine Metabolism LC/MS Pos rank based inverse normal 
2-aminobutyrate Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism LC/MS Pos rank based inverse normal 
2-hydroxybutyrate (AHB) Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism GC/MS natural log 
methionine sulfoxide Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism LC/MS Polar rank based inverse normal 
S-methylcysteine Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism LC/MS Neg rank based inverse normal 
3-(4-hydroxyphenyl)lactate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
3-methoxytyrosine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos rank based inverse normal 
3-phenylpropionate (hydrocinnamate) Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
N-acetylphenylalanine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
o-cresol sulfate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
p-cresol sulfate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
phenol sulfate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
phenylacetate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
phenylacetylglutamine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos natural log 
phenylalanine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos rank based inverse normal 
phenyllactate (PLA) Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
tyrosine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos natural log 
acisoga Amino Acid Polyamine Metabolism LC/MS Pos rank based inverse normal 
3-indoxyl sulfate Amino Acid Tryptophan Metabolism LC/MS Neg natural log 
anthranilate Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
indoleacetate Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
indolelactate Amino Acid Tryptophan Metabolism LC/MS Pos natural log 
indolepropionate Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
kynurenine Amino Acid Tryptophan Metabolism LC/MS Pos natural log 
serotonin (5HT) Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
tryptophan Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
tryptophan betaine Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
arginine Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos rank based inverse normal 
citrulline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
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homocitrulline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
N-methylproline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos rank based inverse normal 
ornithine Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos rank based inverse normal 
pro-hydroxy-pro Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
proline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
trans-4-hydroxyproline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Polar natural log 
urea Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
erythronate Carbohydrate Aminosugar Metabolism LC/MS Polar natural log 
glucuronate Carbohydrate Aminosugar Metabolism LC/MS Polar rank based inverse normal 
trehalose Carbohydrate Disaccharides and Oligosaccharides GC/MS natural log 
mannitol Carbohydrate Fructose, Mannose and Galactose Metabolism GC/MS rank based inverse normal 
mannose Carbohydrate Fructose, Mannose and Galactose Metabolism LC/MS Polar rank based inverse normal 
1,5-anhydroglucitol (1,5-AG) Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Neg rank based inverse normal 
glucose Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Polar rank based inverse normal 
glycerate Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Polar rank based inverse normal 
lactate Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Neg natural log 
arabinose Carbohydrate Pentose Metabolism GC/MS rank based inverse normal 
threitol Carbohydrate Pentose Metabolism GC/MS natural log 
arabonate Cofactors and Vitamins Ascorbate and Aldarate Metabolism GC/MS rank based inverse normal 
threonate Cofactors and Vitamins Ascorbate and Aldarate Metabolism LC/MS Polar not transformed 
bilirubin (E,E) Cofactors and Vitamins Hemoglobin and Porphyrin Metabolism LC/MS Neg rank based inverse normal 
N1-Methyl-2-pyridone-5-carboxamide Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism LC/MS Pos rank based inverse normal 
pantothenate Cofactors and Vitamins Pantothenate and CoA Metabolism LC/MS Pos rank based inverse normal 
alpha-tocopherol Cofactors and Vitamins Tocopherol Metabolism GC/MS natural log 
gamma-tocopherol Cofactors and Vitamins Tocopherol Metabolism GC/MS rank based inverse normal 
pyridoxate Cofactors and Vitamins Vitamin B6 Metabolism LC/MS Neg rank based inverse normal 
phosphate Energy Oxidative Phosphorylation GC/MS natural log 
citrate Energy TCA Cycle GC/MS rank based inverse normal 
malate Energy TCA Cycle LC/MS Neg rank based inverse normal 
succinate Energy TCA Cycle LC/MS Polar rank based inverse normal 
succinylcarnitine Energy TCA Cycle LC/MS Pos rank based inverse normal 
carnitine Lipid Carnitine Metabolism LC/MS Pos rank based inverse normal 
deoxycarnitine Lipid Carnitine Metabolism LC/MS Pos natural log 
5-HETE Lipid Eicosanoid LC/MS Neg rank based inverse normal 
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propionylcarnitine Lipid 
Fatty Acid Metabolism (also BCAA 
Metabolism) LC/MS Pos rank based inverse normal 
acetylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos rank based inverse normal 
cis-4-decenoyl carnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
decanoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
hexanoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos rank based inverse normal 
hydroxybutyrylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
laurylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
octanoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
oleoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
palmitoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
stearoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
2-aminoheptanoate Lipid Fatty Acid, Amino LC/MS Pos rank based inverse normal 
2-aminooctanoate Lipid Fatty Acid, Amino LC/MS Pos rank based inverse normal 
2-hydroxyglutarate Lipid Fatty Acid, Dicarboxylate GC/MS rank based inverse normal 
3-carboxy-4-methyl-5-propyl-2-
furanpropanoate (CMPF) Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
adipate Lipid Fatty Acid, Dicarboxylate GC/MS rank based inverse normal 
azelate (nonanedioate) Lipid Fatty Acid, Dicarboxylate LC/MS Polar rank based inverse normal 
dodecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
eicosanodioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg natural log 
hexadecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg natural log 
octadecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
sebacate (decanedioate) Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
suberate (octanedioate) Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
tetradecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
undecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
13-HODE + 9-HODE Lipid Fatty Acid, Monohydroxy LC/MS Neg rank based inverse normal 
2-hydroxypalmitate Lipid Fatty Acid, Monohydroxy LC/MS Neg rank based inverse normal 
2-hydroxystearate Lipid Fatty Acid, Monohydroxy LC/MS Neg natural log 
glycerol Lipid Glycerolipid Metabolism LC/MS Neg rank based inverse normal 
glycerol 3-phosphate (G3P) Lipid Glycerolipid Metabolism GC/MS rank based inverse normal 
inositol 1-phosphate (I1P) Lipid Inositol Metabolism GC/MS natural log 
myo-inositol Lipid Inositol Metabolism LC/MS Polar natural log 
scyllo-inositol Lipid Inositol Metabolism GC/MS natural log 
3-hydroxybutyrate (BHBA) Lipid Ketone Bodies LC/MS Polar rank based inverse normal 
10-heptadecenoate (17:1n7) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
10-nonadecenoate (19:1n9) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
eicosenoate (20:1n9 or 11) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
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margarate (17:0) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
myristate (14:0) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
myristoleate (14:1n5) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
nonadecanoate (19:0) Lipid Long Chain Fatty Acid LC/MS Neg rank based inverse normal 
oleate (18:1n9) Lipid Long Chain Fatty Acid LC/MS Neg not transformed 
palmitate (16:0) Lipid Long Chain Fatty Acid LC/MS Neg not transformed 
palmitoleate (16:1n7) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
stearate (18:0) Lipid Long Chain Fatty Acid LC/MS Neg rank based inverse normal 
1-arachidonoylglycerophosphocholine 
(20:4n6) Lipid Lysolipid LC/MS Pos rank based inverse normal 
1-
arachidonoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg natural log 
1-arachidonoylglycerophosphoinositol Lipid Lysolipid LC/MS Neg natural log 
1-docosahexaenoylglycerophosphocholine 
(22:6n3) Lipid Lysolipid LC/MS Pos natural log 
1-
docosahexaenoylglycerophosphoethanolami
ne Lipid Lysolipid LC/MS Neg rank based inverse normal 
1-docosapentaenoylglycerophosphocholine 
(22:5n3) Lipid Lysolipid LC/MS Pos natural log 
1-linoleoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg natural log 
1-oleoylglycerophosphocholine (18:1) Lipid Lysolipid LC/MS Pos rank based inverse normal 
1-palmitoleoylglycerophosphocholine 
(16:1) Lipid Lysolipid LC/MS Pos natural log 
1-palmitoylglycerophosphoinositol Lipid Lysolipid LC/MS Neg natural log 
1-palmitoylplasmenylethanolamine Lipid Lysolipid LC/MS Neg natural log 
1-stearoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg natural log 
2-arachidonoylglycerophosphocholine Lipid Lysolipid LC/MS Neg rank based inverse normal 
2-linoleoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg rank based inverse normal 
2-myristoylglycerophosphocholine Lipid Lysolipid LC/MS Pos natural log 
5-dodecenoate (12:1n7) Lipid Medium Chain Fatty Acid LC/MS Neg natural log 
caprate (10:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
caproate (6:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
heptanoate (7:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
laurate (12:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
pelargonate (9:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
1-oleoylglycerol (1-monoolein) Lipid Monoacylglycerol LC/MS Neg rank based inverse normal 
1-stearoylglycerol (1-monostearin) Lipid Monoacylglycerol GC/MS rank based inverse normal 
choline Lipid Phospholipid Metabolism LC/MS Pos rank based inverse normal 
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glycerophosphorylcholine (GPC) Lipid Phospholipid Metabolism LC/MS Pos natural log 
adrenate (22:4n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
arachidonate (20:4n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
dihomo-linoleate (20:2n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
dihomo-linolenate (20:3n3 or n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
docosahexaenoate (DHA; 22:6n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
docosapentaenoate (n3 DPA; 22:5n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
docosapentaenoate (n6 DPA; 22:5n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
eicosapentaenoate (EPA; 20:5n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
linoleate (18:2n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
linolenate [alpha or gamma; (18:3n3 or 6)] Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
stearidonate (18:4n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
glycochenodeoxycholate Lipid Primary Bile Acid Metabolism LC/MS Pos natural log 
glycocholate Lipid Primary Bile Acid Metabolism LC/MS Neg natural log 
taurochenodeoxycholate Lipid Primary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
glycocholenate sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
glycodeoxycholate Lipid Secondary Bile Acid Metabolism LC/MS Pos natural log 
glycolithocholate sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
glycoursodeoxycholate Lipid Secondary Bile Acid Metabolism LC/MS Neg natural log 
taurocholenate sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg natural log 
taurolithocholate 3-sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
21-hydroxypregnenolone disulfate Lipid Steroid LC/MS Neg rank based inverse normal 
4-androsten-3beta,17beta-diol disulfate (1) Lipid Steroid LC/MS Neg rank based inverse normal 
4-androsten-3beta,17beta-diol disulfate (2) Lipid Steroid LC/MS Neg rank based inverse normal 
5alpha-androstan-3beta,17beta-diol 
disulfate Lipid Steroid LC/MS Neg rank based inverse normal 
5alpha-pregnan-3beta,20alpha-diol disulfate Lipid Steroid LC/MS Neg natural log 
androsterone sulfate Lipid Steroid LC/MS Neg rank based inverse normal 
cortisol Lipid Steroid LC/MS Pos natural log 
cortisone Lipid Steroid LC/MS Pos natural log 
dehydroisoandrosterone sulfate (DHEA-S) Lipid Steroid LC/MS Neg natural log 
epiandrosterone sulfate Lipid Steroid LC/MS Neg rank based inverse normal 
pregn steroid monosulfate Lipid Steroid LC/MS Neg natural log 
pregnen-diol disulfate Lipid Steroid LC/MS Neg natural log 
7-alpha-hydroxy-3-oxo-4-cholestenoate (7-
Hoca) Lipid Sterol LC/MS Neg rank based inverse normal 
cholesterol Lipid Sterol GC/MS rank based inverse normal 
hypoxanthine Nucleotide 
Purine Metabolism, (Hypo)Xanthine/Inosine 
containing LC/MS Neg rank based inverse normal 
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urate Nucleotide 
Purine Metabolism, (Hypo)Xanthine/Inosine 
containing LC/MS Neg rank based inverse normal 
xanthine Nucleotide 
Purine Metabolism, (Hypo)Xanthine/Inosine 
containing LC/MS Pos rank based inverse normal 
N1-methyladenosine Nucleotide Purine Metabolism, Adenine containing LC/MS Pos rank based inverse normal 
guanosine Nucleotide Purine Metabolism, Guanine containing LC/MS Pos rank based inverse normal 
5-methyluridine (ribothymidine) Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Neg rank based inverse normal 
N-acetyl-beta-alanine Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Pos natural log 
pseudouridine Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Pos rank based inverse normal 
uridine Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Neg rank based inverse normal 
alanylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
arginylleucine Peptide Dipeptide LC/MS Pos natural log 
arginylphenylalanine Peptide Dipeptide LC/MS Pos rank based inverse normal 
glycylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
glycylphenylalanine Peptide Dipeptide LC/MS Pos natural log 
glycylvaline Peptide Dipeptide LC/MS Pos rank based inverse normal 
histidylleucine Peptide Dipeptide LC/MS Pos natural log 
leucylalanine Peptide Dipeptide LC/MS Pos rank based inverse normal 
leucylasparagine Peptide Dipeptide LC/MS Pos rank based inverse normal 
leucylglycine Peptide Dipeptide LC/MS Pos natural log 
leucylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
leucylserine Peptide Dipeptide LC/MS Pos natural log 
phenylalanylglutamate Peptide Dipeptide LC/MS Pos rank based inverse normal 
phenylalanylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
phenylalanylphenylalanine Peptide Dipeptide LC/MS Pos rank based inverse normal 
phenylalanylserine Peptide Dipeptide LC/MS Pos rank based inverse normal 
pyroglutamylglycine Peptide Dipeptide LC/MS Neg natural log 
serylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
N-acetylcarnosine Peptide Dipeptide Derivative LC/MS Pos natural log 
DSGEGDFXAEGGGVR Peptide Fibrinogen Cleavage Peptide LC/MS Pos rank based inverse normal 
gamma-glutamylalanine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylglutamate Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylisoleucine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylleucine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylphenylalanine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylthreonine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamyltyrosine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylvaline Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
HWESASLLR Peptide Polypeptide LC/MS Pos rank based inverse normal 
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2-hydroxyhippurate (salicylurate) Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
3-methyl catechol sulfate (1) Xenobiotics Benzoate Metabolism LC/MS Neg natural log 
4-hydroxyhippurate Xenobiotics Benzoate Metabolism LC/MS Neg natural log 
4-methylcatechol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
4-vinylphenol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
catechol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
hippurate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
methyl-4-hydroxybenzoate sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
O-methylcatechol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
propyl 4-hydroxybenzoate sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
1,2-propanediol Xenobiotics Chemical GC/MS rank based inverse normal 
2-hydroxyisobutyrate Xenobiotics Chemical GC/MS natural log 
3-hydroxypyridine sulfate Xenobiotics Chemical LC/MS Neg rank based inverse normal 
O-sulfo-L-tyrosine Xenobiotics Chemical LC/MS Neg natural log 
salicylate Xenobiotics Drug LC/MS Neg rank based inverse normal 
erythritol Xenobiotics Food Component/Plant GC/MS rank based inverse normal 
gluconate Xenobiotics Food Component/Plant LC/MS Polar rank based inverse normal 
homostachydrine Xenobiotics Food Component/Plant LC/MS Pos natural log 
piperine Xenobiotics Food Component/Plant LC/MS Pos rank based inverse normal 
stachydrine Xenobiotics Food Component/Plant LC/MS Pos rank based inverse normal 
thymol sulfate Xenobiotics Food Component/Plant LC/MS Neg rank based inverse normal 
1,7-dimethylurate Xenobiotics Xanthine Metabolism LC/MS Neg rank based inverse normal 
1-methylurate Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
5-acetylamino-6-amino-3-methyluracil Xenobiotics Xanthine Metabolism LC/MS Neg rank based inverse normal 
caffeine Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
paraxanthine Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
theobromine Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
theophylline Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
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Supplemental Table 2. Female common variants 
 
traits Name Gene maf.EA beta.EA se.EA p.EA pval.BH.EA maf.AA beta.AA se.AA p.AA pval.BH.AA 
acisoga rs2294757 VNN1 0.38 -0.21 0.03 3.18E-15 5.72E-15 0.16 -0.17 0.03 9.33E-11 1.85E-05 
alanylleucine rs3733402 KLKB1 0.49 -0.24 0.03 1.82E-13 3.12E-13 0.25 -0.12 0.02 3.23E-07 3.13E-02 
2-aminooctanoate rs3813227 ALMS1 0.26 -0.32 0.03 2.48E-25 6.87E-25 0.24 -0.20 0.03 2.21E-13 6.27E-08 
2-aminooctanoate rs6546837 ALMS1 0.26 -0.33 0.03 4.25E-26 1.27E-25 0.24 -0.20 0.03 2.21E-13 6.27E-08 
2-aminooctanoate rs6546838 ALMS1 0.26 -0.33 0.03 6.34E-27 2.85E-26 0.25 -0.20 0.03 2.57E-14 8.51E-09 
2-aminooctanoate rs6546839 ALMS1 0.26 -0.33 0.03 1.38E-26 5.54E-26 0.24 -0.20 0.03 3.44E-13 8.80E-08 
2-aminooctanoate rs2056486 ALMS1 0.25 -0.33 0.03 2.48E-26 8.94E-26 0.25 -0.20 0.03 2.40E-14 8.51E-09 
2-aminooctanoate rs10193972 ALMS1 0.25 -0.33 0.03 3.19E-26 1.04E-25 0.25 -0.20 0.03 1.92E-14 7.61E-09 
2-aminooctanoate rs1052161 ALMS1 0.39 -0.23 0.03 1.21E-16 2.42E-16 0.33 -0.24 0.02 6.79E-23 2.70E-16 
arginine rs3733402 KLKB1 0.49 -0.06 0.01 2.73E-10 4.10E-10 0.25 -0.07 0.01 1.03E-07 1.24E-02 
arginylphenylalanine rs3733402 KLKB1 0.49 -0.17 0.03 1.81E-09 2.61E-09 0.25 -0.13 0.02 8.45E-09 1.20E-03 
dimethylglycine rs1805073 DMGDH 0.28 -0.07 0.03 0.007489 0.008987 0.48 -0.09 0.02 1.74E-07 1.87E-02 
gamma-glutamylisoleucine rs11107 FBXO7 0.37 -0.06 0.02 0.009588 0.011134 0.39 0.09 0.02 2.79E-07 2.84E-02 
histidylleucine rs3733402 KLKB1 0.49 -0.31 0.03 7.84E-20 1.66E-19 0.25 -0.17 0.02 3.55E-13 8.80E-08 
leucylalanine rs3733402 KLKB1 0.49 -0.17 0.03 5.77E-12 9.02E-12 0.25 -0.19 0.02 2.55E-15 1.12E-09 
leucylalanine rs4253301 KLKB1 0.13 -0.14 0.04 0.000245 0.000327 0.06 -0.22 0.04 9.78E-08 1.21E-02 
leucylasparagine rs3733402 KLKB1 0.49 -0.30 0.04 2.88E-12 4.72E-12 0.25 -0.21 0.03 3.39E-10 6.11E-05 
leucylglycine rs3733402 KLKB1 0.49 -0.26 0.03 6.54E-16 1.24E-15 0.25 -0.20 0.03 1.91E-12 4.21E-07 
mannose rs1260326 GCKR 0.42 -0.13 0.01 2.30E-21 5.51E-21 0.13 -0.12 0.02 1.18E-08 1.61E-03 
N1-methyladenosine rs11555566 ADA 0.07 0.17 0.04 7.55E-05 0.000105 0.08 0.14 0.02 2.24E-11 4.67E-06 
N-acetyl-1-methylhistidine rs3813227 ALMS1 0.26 0.44 0.03 5.11E-49 3.07E-48 0.24 0.18 0.02 1.95E-20 1.11E-14 
N-acetyl-1-methylhistidine rs2037814 ALMS1 0.13 -0.10 0.04 0.006627 0.008227 0.11 -0.15 0.03 3.30E-09 5.04E-04 
N-acetyl-1-methylhistidine rs6546837 ALMS1 0.26 0.44 0.03 5.12E-50 6.14E-49 0.24 0.18 0.02 1.95E-20 1.11E-14 
N-acetyl-1-methylhistidine rs6546838 ALMS1 0.26 0.44 0.03 2.43E-49 1.75E-48 0.25 0.18 0.02 4.07E-21 7.65E-15 
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N-acetyl-1-methylhistidine rs6546839 ALMS1 0.26 0.44 0.03 2.08E-49 1.75E-48 0.24 0.18 0.02 9.64E-21 7.65E-15 
N-acetyl-1-methylhistidine rs3820700 ALMS1 0.14 -0.12 0.04 0.001535 0.001973 0.11 -0.16 0.03 1.43E-09 2.27E-04 
N-acetyl-1-methylhistidine rs2056486 ALMS1 0.25 0.44 0.03 3.84E-50 6.14E-49 0.25 0.18 0.02 8.27E-21 7.65E-15 
N-acetyl-1-methylhistidine rs10193972 ALMS1 0.25 0.44 0.03 2.49E-50 6.14E-49 0.25 0.18 0.02 7.26E-21 7.65E-15 
N-acetyl-1-methylhistidine rs1052161 ALMS1 0.39 0.29 0.03 5.11E-27 2.63E-26 0.33 0.15 0.02 2.72E-18 1.35E-12 
N-acetyl-1-methylhistidine rs2272051 DUSP11 0.35 0.27 0.03 5.62E-23 1.44E-22 0.47 0.12 0.02 1.24E-12 2.89E-07 
succinylcarnitine rs2729835 LACTB 0.32 0.15 0.02 5.93E-21 1.33E-20 0.41 0.07 0.01 1.23E-07 1.39E-02 
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Supplemental Table 3. Male common variants 
 
traits Name Gene maf.EA beta.EA se.EA p.EA pval.BH.EA maf.AA beta.AA se.AA p.AA pval.BH.AA 
aminooctanoate rs3813227 ALMS1 0.24 -0.24 0.03 3.22E-13 5.10E-13 0.25 -0.19 0.03 4.09E-08 1.07E-02 
aminooctanoate rs6546837 ALMS1 0.24 -0.24 0.03 3.22E-13 5.10E-13 0.25 -0.19 0.03 4.83E-08 1.14E-02 
aminooctanoate rs6546838 ALMS1 0.24 -0.24 0.03 7.13E-13 9.68E-13 0.27 -0.20 0.03 8.07E-09 2.48E-03 
aminooctanoate rs6546839 ALMS1 0.24 -0.24 0.03 7.13E-13 9.68E-13 0.25 -0.19 0.03 4.17E-08 1.07E-02 
aminooctanoate rs2056486 ALMS1 0.24 -0.24 0.03 3.22E-13 5.10E-13 0.27 -0.20 0.03 8.07E-09 2.48E-03 
aminooctanoate rs10193972 ALMS1 0.24 -0.24 0.03 3.22E-13 5.10E-13 0.26 -0.20 0.03 8.06E-09 2.48E-03 
aminooctanoate rs1052161 ALMS1 0.38 -0.19 0.03 4.59E-10 5.81E-10 0.34 -0.25 0.03 1.33E-15 5.33E-09 
aminooctanoate rs1805074 DMGDH 0.30 -0.11 0.03 8.63E-05 9.11E-05 0.48 -0.12 0.02 6.65E-08 1.48E-02 
aminooctanoate rs1805073 DMGDH 0.30 -0.11 0.03 8.63E-05 9.11E-05 0.49 -0.12 0.02 4.30E-08 1.07E-02 
N1-methyladenosine rs11555566 ADA 0.06 0.22 0.05 9.71E-06 1.15E-05 0.07 0.18 0.03 2.09E-07 3.97E-02 
N-acetyl-1-methylhistidine rs3813227 ALMS1 0.24 0.49 0.03 7.86E-52 3.73E-51 0.25 0.17 0.02 2.57E-11 1.56E-05 
N-acetyl-1-methylhistidine rs6546837 ALMS1 0.24 0.49 0.03 7.86E-52 3.73E-51 0.25 0.17 0.02 3.12E-11 1.56E-05 
N-acetyl-1-methylhistidine rs6546838 ALMS1 0.24 0.48 0.03 2.32E-51 7.35E-51 0.27 0.17 0.02 3.49E-12 2.79E-06 
N-acetyl-1-methylhistidine rs6546839 ALMS1 0.24 0.48 0.03 2.32E-51 7.35E-51 0.25 0.17 0.03 3.01E-11 1.56E-05 
N-acetyl-1-methylhistidine rs2056486 ALMS1 0.24 0.49 0.03 7.86E-52 3.73E-51 0.27 0.17 0.02 3.49E-12 2.79E-06 
N-acetyl-1-methylhistidine rs10193972 ALMS1 0.24 0.49 0.03 7.86E-52 3.73E-51 0.26 0.17 0.02 3.35E-12 2.79E-06 
N-acetyl-1-methylhistidine rs1052161 ALMS1 0.38 0.28 0.03 6.47E-23 1.76E-22 0.34 0.17 0.02 3.67E-14 7.33E-08 
N-acetyl-1-methylhistidine rs2272051 DUSP11 0.35 0.24 0.03 4.30E-17 1.02E-16 0.49 0.12 0.02 5.88E-09 2.35E-03 
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Supplemental Table 4. Sex-specific burden test 
 
    EA AA 
sex traits gene chr N nsnp MAC beta se p Fdr-q N nsnp MAC beta se p Fdr-q 
male dimethylglycine DMGDH 5 701 6 26 0.64 0.10 1.48E-11 4.59E-10 720 10 26 0.44 0.07 1.73E-09 1.21E-03 
male N-acetylalanine ACY1 3 701 3 15 0.23 0.04 6.00E-08 9.30E-07 720 5 81 0.15 0.02 1.63E-13 5.68E-07 
female N-acetylalanine ACY1 3 827 3 17 0.23 0.04 8.22E-10 1.64E-08 1292 7 151 0.17 0.02 1.06E-27 2.03E-21 
female isobutyrylcarnitine ACAD8 11 827 1 39 0.46 0.09 1.44E-07 1.44E-06 1292 3 90 0.32 0.05 3.25E-10 2.07E-04 
female indolelactate CCBL1 9 827 3 17 0.29 0.07 2.41E-05 1.61E-04 1292 9 36 0.36 0.05 1.65E-12 2.10E-06 
female dimethylglycine DMGDH 5 827 6 39 0.28 0.08 0.000389 1.94E-03 1292 11 66 0.58 0.05 2.36E-29 9.02E-23 
female N-acetylthreonine ACY1 3 827 3 17 0.23 0.08 0.001936 6.74E-03 1292 7 151 0.13 0.02 2.77E-08 8.83E-03 
female phenyllactate (PLA) CCBL1 9 827 3 17 0.23 0.07 0.002022 6.74E-03 1292 9 36 0.29 0.05 1.28E-08 5.46E-03 
female 3-(4-hydroxyphenyl)lactate CCBL1 9 827 3 17 0.23 0.08 0.002634 7.52E-03 1292 9 36 0.29 0.05 2.33E-08 8.09E-03 
 
 
Supplemental Table 5. Z test for sex-specific burden test 
   EA AA 
traits Gene chr cmafUsed.male cmafUsed.female Z.tst p.val cmafUsed.male. cmafUsed.female Z.tst p.val FDR-q 
leucylleucine NMT2 10 0.009 0.007 -0.66 0.51 0.003 0.004 -5.45 4.97E-08 0.03 
10-nonadecenoate (19:1n9) AGER 6 0.059 0.053 -1.50 0.13 0.051 0.040 5.66 1.56E-08 0.03 
phenylalanylphenylalanine BAG4 8 0.008 0.007 -1.22 0.22 0.003 0.004 -5.51 3.59E-08 0.03 
phenylalanylphenylalanine SPATA17 1 0.027 0.026 -0.61 0.54 0.019 0.018 -5.60 2.13E-08 0.03 
S-methylcysteine IKZF4 12 0.010 0.008 0.10 0.92 0.003 0.008 -5.57 2.54E-08 0.03 
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Appendix B. supplemental materials for Chapter 3 
Supplemental Table 1. List of 271 metabolites and transformation methods applied 
Metabolites Super_Pathway Sub_Pathway Platform Transformation 
alanine Amino Acid Alanine and Aspartate Metabolism LC/MS Pos rank based inverse normal 
asparagine Amino Acid Alanine and Aspartate Metabolism LC/MS Pos rank based inverse normal 
aspartate Amino Acid Alanine and Aspartate Metabolism LC/MS Polar rank based inverse normal 
N-acetylalanine Amino Acid Alanine and Aspartate Metabolism LC/MS Neg natural log 
creatine Amino Acid Creatine Metabolism LC/MS Pos rank based inverse normal 
creatinine Amino Acid Creatine Metabolism LC/MS Pos rank based inverse normal 
glutamate Amino Acid Glutamate Metabolism LC/MS Pos natural log 
pyroglutamine Amino Acid Glutamate Metabolism LC/MS Pos rank based inverse normal 
5-oxoproline Amino Acid Glutathione Metabolism LC/MS Neg not transformed 
betaine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos not transformed 
dimethylglycine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos natural log 
glycine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos natural log 
N-acetylglycine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Neg rank based inverse normal 
N-acetylthreonine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Neg natural log 
serine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos rank based inverse normal 
threonine Amino Acid Glycine, Serine and Threonine Metabolism LC/MS Pos rank based inverse normal 
4-guanidinobutanoate Amino Acid Guanidino and Acetamido Metabolism LC/MS Pos natural log 
3-methylhistidine Amino Acid Histidine Metabolism LC/MS Neg rank based inverse normal 
histidine Amino Acid Histidine Metabolism LC/MS Neg rank based inverse normal 
N-acetyl-1-methylhistidine Amino Acid Histidine Metabolism LC/MS Pos natural log 
trans-urocanate Amino Acid Histidine Metabolism LC/MS Pos natural log 
2-methylbutyrylcarnitine (C5) Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
3-hydroxyisobutyrate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Polar natural log 
3-methyl-2-oxovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
alpha-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
beta-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
beta-hydroxyisovaleroylcarnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
isobutyrylcarnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
isoleucine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
isovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Neg rank based inverse normal 
isovalerylcarnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
leucine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
tiglyl carnitine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
valine Amino Acid Leucine, Isoleucine and Valine Metabolism LC/MS Pos natural log 
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glutarate (pentanedioate) Amino Acid Lysine Metabolism LC/MS Polar rank based inverse normal 
glutarylcarnitine (C5) Amino Acid Lysine Metabolism LC/MS Pos rank based inverse normal 
lysine Amino Acid Lysine Metabolism LC/MS Polar rank based inverse normal 
N6-acetyllysine Amino Acid Lysine Metabolism LC/MS Pos rank based inverse normal 
pipecolate Amino Acid Lysine Metabolism LC/MS Pos rank based inverse normal 
2-aminobutyrate Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism LC/MS Pos rank based inverse normal 
2-hydroxybutyrate (AHB) Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism GC/MS natural log 
methionine sulfoxide Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism LC/MS Polar rank based inverse normal 
S-methylcysteine Amino Acid 
Methionine, Cysteine, SAM and Taurine 
Metabolism LC/MS Neg rank based inverse normal 
3-(4-hydroxyphenyl)lactate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
3-methoxytyrosine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos rank based inverse normal 
3-phenylpropionate (hydrocinnamate) Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
N-acetylphenylalanine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
o-cresol sulfate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
p-cresol sulfate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
phenol sulfate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
phenylacetate Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg natural log 
phenylacetylglutamine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos natural log 
phenylalanine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos rank based inverse normal 
phenyllactate (PLA) Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Neg rank based inverse normal 
tyrosine Amino Acid Phenylalanine and Tyrosine Metabolism LC/MS Pos natural log 
acisoga Amino Acid Polyamine Metabolism LC/MS Pos rank based inverse normal 
3-indoxyl sulfate Amino Acid Tryptophan Metabolism LC/MS Neg natural log 
anthranilate Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
indoleacetate Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
indolelactate Amino Acid Tryptophan Metabolism LC/MS Pos natural log 
indolepropionate Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
kynurenine Amino Acid Tryptophan Metabolism LC/MS Pos natural log 
serotonin (5HT) Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
tryptophan Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
tryptophan betaine Amino Acid Tryptophan Metabolism LC/MS Pos rank based inverse normal 
arginine Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos rank based inverse normal 
citrulline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
homocitrulline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
N-methylproline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos rank based inverse normal 
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ornithine Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos rank based inverse normal 
pro-hydroxy-pro Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
proline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
trans-4-hydroxyproline Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Polar natural log 
urea Amino Acid Urea cycle; Arginine and Proline Metabolism LC/MS Pos natural log 
erythronate Carbohydrate Aminosugar Metabolism LC/MS Polar natural log 
glucuronate Carbohydrate Aminosugar Metabolism LC/MS Polar rank based inverse normal 
trehalose Carbohydrate Disaccharides and Oligosaccharides GC/MS natural log 
mannitol Carbohydrate Fructose, Mannose and Galactose Metabolism GC/MS rank based inverse normal 
mannose Carbohydrate Fructose, Mannose and Galactose Metabolism LC/MS Polar rank based inverse normal 
1,5-anhydroglucitol (1,5-AG) Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Neg rank based inverse normal 
glucose Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Polar rank based inverse normal 
glycerate Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Polar rank based inverse normal 
lactate Carbohydrate 
Glycolysis, Gluconeogenesis, and Pyruvate 
Metabolism LC/MS Neg natural log 
arabinose Carbohydrate Pentose Metabolism GC/MS rank based inverse normal 
threitol Carbohydrate Pentose Metabolism GC/MS natural log 
arabonate Cofactors and Vitamins Ascorbate and Aldarate Metabolism GC/MS rank based inverse normal 
threonate Cofactors and Vitamins Ascorbate and Aldarate Metabolism LC/MS Polar not transformed 
bilirubin (E,E) Cofactors and Vitamins Hemoglobin and Porphyrin Metabolism LC/MS Neg rank based inverse normal 
N1-Methyl-2-pyridone-5-carboxamide Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism LC/MS Pos rank based inverse normal 
pantothenate Cofactors and Vitamins Pantothenate and CoA Metabolism LC/MS Pos rank based inverse normal 
alpha-tocopherol Cofactors and Vitamins Tocopherol Metabolism GC/MS natural log 
gamma-tocopherol Cofactors and Vitamins Tocopherol Metabolism GC/MS rank based inverse normal 
pyridoxate Cofactors and Vitamins Vitamin B6 Metabolism LC/MS Neg rank based inverse normal 
phosphate Energy Oxidative Phosphorylation GC/MS natural log 
citrate Energy TCA Cycle GC/MS rank based inverse normal 
malate Energy TCA Cycle LC/MS Neg rank based inverse normal 
succinate Energy TCA Cycle LC/MS Polar rank based inverse normal 
succinylcarnitine Energy TCA Cycle LC/MS Pos rank based inverse normal 
carnitine Lipid Carnitine Metabolism LC/MS Pos rank based inverse normal 
deoxycarnitine Lipid Carnitine Metabolism LC/MS Pos natural log 
5-HETE Lipid Eicosanoid LC/MS Neg rank based inverse normal 
propionylcarnitine Lipid 
Fatty Acid Metabolism (also BCAA 
Metabolism) LC/MS Pos rank based inverse normal 
acetylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos rank based inverse normal 
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cis-4-decenoyl carnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
decanoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
hexanoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos rank based inverse normal 
hydroxybutyrylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
laurylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
octanoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
oleoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
palmitoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
stearoylcarnitine Lipid Fatty Acid Metabolism(Acyl Carnitine) LC/MS Pos natural log 
2-aminoheptanoate Lipid Fatty Acid, Amino LC/MS Pos rank based inverse normal 
2-aminooctanoate Lipid Fatty Acid, Amino LC/MS Pos rank based inverse normal 
2-hydroxyglutarate Lipid Fatty Acid, Dicarboxylate GC/MS rank based inverse normal 
3-carboxy-4-methyl-5-propyl-2-
furanpropanoate (CMPF) Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
adipate Lipid Fatty Acid, Dicarboxylate GC/MS rank based inverse normal 
azelate (nonanedioate) Lipid Fatty Acid, Dicarboxylate LC/MS Polar rank based inverse normal 
dodecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
eicosanodioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg natural log 
hexadecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg natural log 
octadecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
sebacate (decanedioate) Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
suberate (octanedioate) Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
tetradecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
undecanedioate Lipid Fatty Acid, Dicarboxylate LC/MS Neg rank based inverse normal 
13-HODE + 9-HODE Lipid Fatty Acid, Monohydroxy LC/MS Neg rank based inverse normal 
2-hydroxypalmitate Lipid Fatty Acid, Monohydroxy LC/MS Neg rank based inverse normal 
2-hydroxystearate Lipid Fatty Acid, Monohydroxy LC/MS Neg natural log 
glycerol Lipid Glycerolipid Metabolism LC/MS Neg rank based inverse normal 
glycerol 3-phosphate (G3P) Lipid Glycerolipid Metabolism GC/MS rank based inverse normal 
inositol 1-phosphate (I1P) Lipid Inositol Metabolism GC/MS natural log 
myo-inositol Lipid Inositol Metabolism LC/MS Polar natural log 
scyllo-inositol Lipid Inositol Metabolism GC/MS natural log 
3-hydroxybutyrate (BHBA) Lipid Ketone Bodies LC/MS Polar rank based inverse normal 
10-heptadecenoate (17:1n7) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
10-nonadecenoate (19:1n9) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
eicosenoate (20:1n9 or 11) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
margarate (17:0) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
myristate (14:0) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
myristoleate (14:1n5) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
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nonadecanoate (19:0) Lipid Long Chain Fatty Acid LC/MS Neg rank based inverse normal 
oleate (18:1n9) Lipid Long Chain Fatty Acid LC/MS Neg not transformed 
palmitate (16:0) Lipid Long Chain Fatty Acid LC/MS Neg not transformed 
palmitoleate (16:1n7) Lipid Long Chain Fatty Acid LC/MS Neg natural log 
stearate (18:0) Lipid Long Chain Fatty Acid LC/MS Neg rank based inverse normal 
1-arachidonoylglycerophosphocholine 
(20:4n6) Lipid Lysolipid LC/MS Pos rank based inverse normal 
1-
arachidonoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg natural log 
1-arachidonoylglycerophosphoinositol Lipid Lysolipid LC/MS Neg natural log 
1-docosahexaenoylglycerophosphocholine 
(22:6n3) Lipid Lysolipid LC/MS Pos natural log 
1-
docosahexaenoylglycerophosphoethanolami
ne Lipid Lysolipid LC/MS Neg rank based inverse normal 
1-docosapentaenoylglycerophosphocholine 
(22:5n3) Lipid Lysolipid LC/MS Pos natural log 
1-linoleoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg natural log 
1-oleoylglycerophosphocholine (18:1) Lipid Lysolipid LC/MS Pos rank based inverse normal 
1-palmitoleoylglycerophosphocholine 
(16:1) Lipid Lysolipid LC/MS Pos natural log 
1-palmitoylglycerophosphoinositol Lipid Lysolipid LC/MS Neg natural log 
1-palmitoylplasmenylethanolamine Lipid Lysolipid LC/MS Neg natural log 
1-stearoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg natural log 
2-arachidonoylglycerophosphocholine Lipid Lysolipid LC/MS Neg rank based inverse normal 
2-linoleoylglycerophosphoethanolamine Lipid Lysolipid LC/MS Neg rank based inverse normal 
2-myristoylglycerophosphocholine Lipid Lysolipid LC/MS Pos natural log 
5-dodecenoate (12:1n7) Lipid Medium Chain Fatty Acid LC/MS Neg natural log 
caprate (10:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
caproate (6:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
heptanoate (7:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
laurate (12:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
pelargonate (9:0) Lipid Medium Chain Fatty Acid LC/MS Neg rank based inverse normal 
1-oleoylglycerol (1-monoolein) Lipid Monoacylglycerol LC/MS Neg rank based inverse normal 
1-stearoylglycerol (1-monostearin) Lipid Monoacylglycerol GC/MS rank based inverse normal 
choline Lipid Phospholipid Metabolism LC/MS Pos rank based inverse normal 
glycerophosphorylcholine (GPC) Lipid Phospholipid Metabolism LC/MS Pos natural log 
adrenate (22:4n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
arachidonate (20:4n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
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dihomo-linoleate (20:2n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
dihomo-linolenate (20:3n3 or n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
docosahexaenoate (DHA; 22:6n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
docosapentaenoate (n3 DPA; 22:5n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
docosapentaenoate (n6 DPA; 22:5n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
eicosapentaenoate (EPA; 20:5n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
linoleate (18:2n6) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
linolenate [alpha or gamma; (18:3n3 or 6)] Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg natural log 
stearidonate (18:4n3) Lipid Polyunsaturated Fatty Acid (n3 and n6) LC/MS Neg rank based inverse normal 
glycochenodeoxycholate Lipid Primary Bile Acid Metabolism LC/MS Pos natural log 
glycocholate Lipid Primary Bile Acid Metabolism LC/MS Neg natural log 
taurochenodeoxycholate Lipid Primary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
glycocholenate sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
glycodeoxycholate Lipid Secondary Bile Acid Metabolism LC/MS Pos natural log 
glycolithocholate sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
glycoursodeoxycholate Lipid Secondary Bile Acid Metabolism LC/MS Neg natural log 
taurocholenate sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg natural log 
taurolithocholate 3-sulfate Lipid Secondary Bile Acid Metabolism LC/MS Neg rank based inverse normal 
21-hydroxypregnenolone disulfate Lipid Steroid LC/MS Neg rank based inverse normal 
4-androsten-3beta,17beta-diol disulfate (1) Lipid Steroid LC/MS Neg rank based inverse normal 
4-androsten-3beta,17beta-diol disulfate (2) Lipid Steroid LC/MS Neg rank based inverse normal 
5alpha-androstan-3beta,17beta-diol 
disulfate Lipid Steroid LC/MS Neg rank based inverse normal 
5alpha-pregnan-3beta,20alpha-diol disulfate Lipid Steroid LC/MS Neg natural log 
androsterone sulfate Lipid Steroid LC/MS Neg rank based inverse normal 
cortisol Lipid Steroid LC/MS Pos natural log 
cortisone Lipid Steroid LC/MS Pos natural log 
dehydroisoandrosterone sulfate (DHEA-S) Lipid Steroid LC/MS Neg natural log 
epiandrosterone sulfate Lipid Steroid LC/MS Neg rank based inverse normal 
pregn steroid monosulfate Lipid Steroid LC/MS Neg natural log 
pregnen-diol disulfate Lipid Steroid LC/MS Neg natural log 
7-alpha-hydroxy-3-oxo-4-cholestenoate (7-
Hoca) Lipid Sterol LC/MS Neg rank based inverse normal 
cholesterol Lipid Sterol GC/MS rank based inverse normal 
hypoxanthine Nucleotide 
Purine Metabolism, (Hypo)Xanthine/Inosine 
containing LC/MS Neg rank based inverse normal 
urate Nucleotide 
Purine Metabolism, (Hypo)Xanthine/Inosine 
containing LC/MS Neg rank based inverse normal 
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xanthine Nucleotide 
Purine Metabolism, (Hypo)Xanthine/Inosine 
containing LC/MS Pos rank based inverse normal 
N1-methyladenosine Nucleotide Purine Metabolism, Adenine containing LC/MS Pos rank based inverse normal 
guanosine Nucleotide Purine Metabolism, Guanine containing LC/MS Pos rank based inverse normal 
5-methyluridine (ribothymidine) Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Neg rank based inverse normal 
N-acetyl-beta-alanine Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Pos natural log 
pseudouridine Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Pos rank based inverse normal 
uridine Nucleotide Pyrimidine Metabolism, Uracil containing LC/MS Neg rank based inverse normal 
alanylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
arginylleucine Peptide Dipeptide LC/MS Pos natural log 
arginylphenylalanine Peptide Dipeptide LC/MS Pos rank based inverse normal 
glycylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
glycylphenylalanine Peptide Dipeptide LC/MS Pos natural log 
glycylvaline Peptide Dipeptide LC/MS Pos rank based inverse normal 
histidylleucine Peptide Dipeptide LC/MS Pos natural log 
leucylalanine Peptide Dipeptide LC/MS Pos rank based inverse normal 
leucylasparagine Peptide Dipeptide LC/MS Pos rank based inverse normal 
leucylglycine Peptide Dipeptide LC/MS Pos natural log 
leucylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
leucylserine Peptide Dipeptide LC/MS Pos natural log 
phenylalanylglutamate Peptide Dipeptide LC/MS Pos rank based inverse normal 
phenylalanylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
phenylalanylphenylalanine Peptide Dipeptide LC/MS Pos rank based inverse normal 
phenylalanylserine Peptide Dipeptide LC/MS Pos rank based inverse normal 
pyroglutamylglycine Peptide Dipeptide LC/MS Neg natural log 
serylleucine Peptide Dipeptide LC/MS Pos rank based inverse normal 
N-acetylcarnosine Peptide Dipeptide Derivative LC/MS Pos natural log 
DSGEGDFXAEGGGVR Peptide Fibrinogen Cleavage Peptide LC/MS Pos rank based inverse normal 
gamma-glutamylalanine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylglutamate Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylisoleucine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylleucine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylphenylalanine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylthreonine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamyltyrosine Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
gamma-glutamylvaline Peptide Gamma-glutamyl Amino Acid LC/MS Pos rank based inverse normal 
HWESASLLR Peptide Polypeptide LC/MS Pos rank based inverse normal 
2-hydroxyhippurate (salicylurate) Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
3-methyl catechol sulfate (1) Xenobiotics Benzoate Metabolism LC/MS Neg natural log 
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4-hydroxyhippurate Xenobiotics Benzoate Metabolism LC/MS Neg natural log 
4-methylcatechol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
4-vinylphenol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
catechol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
hippurate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
methyl-4-hydroxybenzoate sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
O-methylcatechol sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
propyl 4-hydroxybenzoate sulfate Xenobiotics Benzoate Metabolism LC/MS Neg rank based inverse normal 
1,2-propanediol Xenobiotics Chemical GC/MS rank based inverse normal 
2-hydroxyisobutyrate Xenobiotics Chemical GC/MS natural log 
3-hydroxypyridine sulfate Xenobiotics Chemical LC/MS Neg rank based inverse normal 
O-sulfo-L-tyrosine Xenobiotics Chemical LC/MS Neg natural log 
salicylate Xenobiotics Drug LC/MS Neg rank based inverse normal 
erythritol Xenobiotics Food Component/Plant GC/MS rank based inverse normal 
gluconate Xenobiotics Food Component/Plant LC/MS Polar rank based inverse normal 
homostachydrine Xenobiotics Food Component/Plant LC/MS Pos natural log 
piperine Xenobiotics Food Component/Plant LC/MS Pos rank based inverse normal 
stachydrine Xenobiotics Food Component/Plant LC/MS Pos rank based inverse normal 
thymol sulfate Xenobiotics Food Component/Plant LC/MS Neg rank based inverse normal 
1,7-dimethylurate Xenobiotics Xanthine Metabolism LC/MS Neg rank based inverse normal 
1-methylurate Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
5-acetylamino-6-amino-3-methyluracil Xenobiotics Xanthine Metabolism LC/MS Neg rank based inverse normal 
caffeine Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
paraxanthine Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
theobromine Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
theophylline Xenobiotics Xanthine Metabolism LC/MS Pos rank based inverse normal 
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Supplemental Table 2. Genes discovered through jointly testing the genetic main effects and gene-sex interactions 
   AA EA 
Metabolites Gene Chr 
N_S
NP 
Fix.pvalu
e 
Random.
pvalue 
Joint.pva
lue 
Fdr.p.joi
nt 
N_S
NP 
Fix.pvalu
e 
Random.
pvalue 
Joint.pva
lue 
Postfdr.p
.joint 
2-aminooctanoate ALMS1 2 52 5.24E-02 1.26E-01 2.16E-07 2.28E-02 37 5.24E-02 3.02E-02 2.15E-03 8.17E-03 
2-aminooctanoate ACY1 3 7 2.64E-02 2.89E-02 2.19E-08 4.63E-03 3 4.93E-02 6.23E-02 1.29E-01 1.96E-01 
arachidonate (20:4n6) PLA2G7 6 7 6.50E-01 6.67E-01 6.19E-07 4.62E-02 7 1.68E-02 1.25E-02 1.86E-02 5.06E-02 
1-
arachidonoylglyceropho
sphoethanolamine MAP10 1 13 4.11E-03 4.22E-03 1.72E-07 1.94E-02 5 6.11E-01 7.62E-01 6.88E-01 7.68E-01 
arginylleucine NPC2 14 4 9.95E-02 8.02E-02 5.26E-07 4.34E-02 5 2.22E-01 4.75E-01 1.79E-01 2.61E-01 
arginylleucine NDRG3 20 4 2.79E-01 2.26E-01 4.55E-08 6.69E-03 NA NA NA NA NA 
cholesterol PCSK9 1 18 9.52E-01 9.59E-01 6.90E-10 2.12E-04 6 6.84E-01 6.04E-01 6.72E-02 1.14E-01 
deoxycarnitine SLC25A45 11 8 6.48E-01 6.62E-01 1.70E-07 1.94E-02 5 3.89E-01 4.51E-01 4.37E-03 1.51E-02 
deoxycarnitine C1QTNF1 17 5 9.57E-03 7.16E-03 6.29E-07 4.62E-02 5 6.66E-01 7.47E-01 2.45E-01 3.21E-01 
dimethylglycine DMGDH 5 12 8.01E-02 6.50E-02 4.57E-36 7.73E-30 8 6.23E-01 6.33E-01 2.56E-09 1.95E-08 
DSGEGDFXAEGGGV
R CPN1 10 3 9.52E-01 9.14E-01 5.25E-10 1.77E-04 NA NA NA NA NA 
eicosanodioate ALDH7A1 5 8 8.55E-07 5.64E-07 5.62E-07 4.52E-02 4 1.80E-01 1.70E-01 3.12E-01 3.82E-01 
gamma-
glutamylphenylalanine COPE 19 3 7.02E-08 7.53E-08 9.65E-08 1.31E-02 3 5.60E-01 6.91E-01 8.47E-01 8.70E-01 
glutarylcarnitine (C5) RNASEH2A 19 5 5.05E-01 4.98E-01 2.88E-08 5.72E-03 3 9.32E-01 9.20E-01 2.65E-01 3.35E-01 
glycochenodeoxycholat
e SLC10A1 14 8 2.11E-01 2.96E-01 5.75E-07 4.52E-02 NA NA NA NA NA 
glycocholate LRP4 11 18 7.30E-06 5.14E-06 3.98E-07 3.54E-02 12 9.37E-01 9.48E-01 9.89E-01 9.89E-01 
glycocholate SLC10A1 14 8 1.81E-01 2.44E-01 2.01E-10 8.52E-05 NA NA NA NA NA 
glycocholenate sulfate CYP27A1 2 12 9.12E-01 9.08E-01 1.34E-07 1.74E-02 7 3.26E-01 3.57E-01 6.22E-02 1.13E-01 
glycocholenate sulfate HRASLS5 11 6 7.41E-01 7.93E-01 3.24E-08 5.78E-03 7 9.12E-02 1.29E-01 2.26E-01 3.07E-01 
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glycocholenate sulfate SLCO1B1 12 9 9.60E-01 9.42E-01 1.26E-08 2.84E-03 NA NA NA NA NA 
hexadecanedioate SLCO1B1 12 9 2.28E-01 2.39E-01 5.25E-10 1.77E-04 NA NA NA NA NA 
histidine HAL 12 11 9.90E-01 9.84E-01 7.07E-07 4.98E-02 14 1.66E-01 1.61E-01 8.69E-04 4.13E-03 
histidylleucine NPC2 14 4 1.70E-03 1.25E-03 3.74E-08 6.02E-03 5 1.35E-01 2.73E-01 4.83E-02 9.67E-02 
13-HODE + 9-HODE PLA2G7 6 7 7.24E-02 7.82E-02 3.44E-08 5.81E-03 7 3.57E-01 4.03E-01 5.85E-01 6.74E-01 
3-(4-
hydroxyphenyl)lactate CCBL1 9 9 8.97E-01 9.40E-01 4.57E-14 2.57E-08 4 7.91E-01 7.87E-01 2.51E-02 6.11E-02 
indolelactate CCBL1 9 9 5.77E-01 6.23E-01 5.15E-23 5.81E-17 4 3.38E-01 2.99E-01 2.70E-04 1.47E-03 
isobutyrylcarnitine ACAD8 11 3 3.87E-01 4.08E-01 6.98E-13 3.37E-07 3 1.91E-01 1.99E-01 2.58E-10 2.45E-09 
kynurenine ZNF827 4 8 1.66E-02 2.52E-02 2.50E-07 2.48E-02 7 4.31E-01 3.74E-01 3.71E-02 8.28E-02 
kynurenine IDO1 8 6 8.57E-01 8.95E-01 3.99E-09 1.05E-03 NA NA NA NA NA 
leucylasparagine KLKB1 4 13 4.52E-01 4.65E-01 4.87E-07 4.12E-02 10 1.61E-01 1.37E-01 1.75E-02 5.06E-02 
leucylglycine NDRG3 20 4 7.57E-01 6.56E-01 7.84E-08 1.10E-02 NA NA NA NA NA 
leucylserine NPC2 14 4 5.83E-04 3.79E-04 1.93E-07 2.10E-02 5 2.93E-02 6.59E-02 6.78E-03 2.15E-02 
linolenate [alpha or 
gamma; (18:3n3 or 6)] COL3A1 2 13 2.05E-01 2.37E-01 1.41E-07 1.76E-02 7 1.04E-01 9.31E-02 4.01E-02 8.47E-02 
4-methylcatechol 
sulfate PSME4 2 12 8.52E-01 8.58E-01 6.18E-09 1.49E-03 9 5.27E-01 5.06E-01 7.36E-01 7.93E-01 
N1-methyladenosine ADA 20 5 5.64E-02 5.59E-02 2.69E-07 2.60E-02 NA NA NA NA NA 
N-acetyl-1-
methylhistidine ALMS1 2 52 9.88E-01 9.77E-01 4.05E-09 1.05E-03 37 4.60E-01 4.45E-01 3.32E-11 4.21E-10 
N-acetyl-1-
methylhistidine DDTL 22 2 3.65E-08 1.18E-07 2.24E-07 2.29E-02 NA NA NA NA NA 
N-acetylalanine ACY1 3 7 3.76E-01 3.82E-01 4.43E-52 1.50E-45 3 4.65E-01 4.74E-01 4.07E-23 1.55E-21 
N-acetylalanine ADCY5 3 7 1.06E-06 1.71E-06 7.02E-07 4.98E-02 9 2.72E-01 2.96E-01 6.90E-02 1.14E-01 
N-acetyl-beta-alanine CRYGA 2 4 6.98E-01 8.47E-01 4.38E-07 3.80E-02 4 1.99E-01 2.06E-01 3.50E-01 4.16E-01 
N-acetyl-beta-alanine PTER 10 7 6.20E-01 5.55E-01 3.07E-08 5.77E-03 4 9.58E-02 8.68E-02 9.84E-12 1.87E-10 
N-acetylcarnosine SEPT-9 17 3 4.60E-02 8.83E-02 3.31E-07 3.11E-02 6 1.56E-01 1.85E-01 2.23E-01 3.07E-01 
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N-acetylglycine ACY1 3 7 3.30E-01 3.28E-01 3.93E-08 6.05E-03 3 7.68E-01 7.81E-01 1.58E-03 6.66E-03 
N-acetylthreonine ACY1 3 7 2.68E-01 2.72E-01 8.01E-16 6.77E-10 3 2.39E-01 2.53E-01 2.71E-05 1.72E-04 
10-nonadecenoate 
(19:1n9) AGER 6 7 4.32E-07 2.16E-07 3.95E-07 3.54E-02 9 4.06E-01 3.25E-01 5.74E-02 1.09E-01 
phenyllactate (PLA) CCBL1 9 9 4.13E-01 4.66E-01 2.73E-14 1.85E-08 4 4.43E-01 3.76E-01 2.57E-02 6.11E-02 
taurocholenate sulfate OR2C3 1 7 6.14E-07 4.38E-07 6.26E-07 4.62E-02 3 5.91E-01 5.65E-01 7.51E-01 7.93E-01 
tiglyl carnitine DARS 2 6 7.52E-06 2.75E-06 1.53E-07 1.85E-02 2 1.47E-01 1.16E-01 7.61E-02 1.21E-01 
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Supplemental Table 3 Genes revealed as suggestively significant (false discovery rate <20%) through rareGE fix/random effect 
interaction test 
   AA EA 
Metabolites Gene Chr 
N_S
NP 
Fix.pvalu
e 
Random.pvalu
e 
Fdr.fix.
p 
Fdr.random.
p 
N_SN
P 
Fix.pvalu
e 
Random.pvalu
e 
gamma-
glutamylphenylalanine COPE 19 3 7.02E-08 7.53E-08 0.12 0.20 3 0.56 0.69 
N-acetyl-1-methylhistidine DDTL 22 2 3.65E-08 1.18E-07 0.12 0.20 NA NA NA 
arginylleucine SPACA4 19 2 1.33E-07 2.77E-05 0.15 0.73 NA NA NA 
 
 
 
 
Supplemental Table 4 Genes revealed as suggestively significant (false discovery rate <20%) through MiSTi interaction test 
   AA EA 
Metabolites Gene 
Ch
r 
N_S
NP 
Fisher.p
value 
BurdenComp.
pvalue 
VarComp.p
value 
Fdr.Fish
er.p 
N_SN
P 
Fisher.
pvalue 
BurdenComp
.pvalue 
VarComp.p
value 
bilirubin 
(E,E) 
P
OLH 6 7 
5
.18E-08 
2.14E
-05 
1.16
E-04 
0
.09 4 
0
.57 0.46 0.51 
N-acetyl-
1-methylhistidine 
D
DTL 
2
2 2 
5
.41E-08 
8.64E
-04 
3.01
E-06 
0
.09 
N
A 
N
A NA NA 
arginylleu
cine 
G
NL1 6 3 
1
.21E-07 
1.15E
-02 
5.30
E-07 
0
.13 5 
0
.49 0.87 0.21 
arginylleu
cine 
P
TPN5 
1
1 3 
1
.86E-07 
5.11E
-04 
1.87
E-05 
0
.15 
N
A 
N
A NA NA 
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Supplemental Figure 1. QQ plots of joint test results for each metabolite  
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